Marc Feldmann

Q: What Schools Are Affiliated With Marc Feldmann

Marc Feldmann is affiliated with the following schools: Imperial College London, University of Oxford, University College London, University of Basel, University of Melbourne Faculty of Medicine, Dentistry and Health Sciences, University of Vienna

Marc Feldmann's AcademicInfluence.com Rankings

Marc Feldmann

Biology

#1123

World Rank

#1923

Historical Rank

Immunology

#35

World Rank

#39

Historical Rank

biology Degrees

Download Badge

Biology

Marc Feldmann's Degrees

Doctorate Medicine University of Vienna
PhD Immunology University of Vienna

Why Is Marc Feldmann Influential?

(Suggest an Edit or Addition)

According to Wikipedia, Sir Marc Feldmann, , is an Australian-educated British immunologist. He is a professor at the University of Oxford and a senior research fellow at Somerville College, Oxford. Biography Feldmann was born 2 December 1944 in Lvov to a Jewish family who managed to get to France immediately postwar. He emigrated from France to Australia at age eight. After graduating with an MBBS degree from the University of Melbourne in 1967, he earned a Ph.D. in Immunology at the Walter and Eliza Hall Institute of Medical Research in 1972 with Sir Gustav Nossal.

(See a Problem?)

Marc Feldmann's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. (2000) (3063)
Infliximab (chimeric anti-tumour necrosis factor α monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial (1999) (2434)
Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor α (cA2) versus placebo in rheumatoid arthritis (1994) (1782)
Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis. (1998) (1712)
Role of cytokines in rheumatoid arthritis. (1996) (1667)
An inflammatory cytokine signature predicts COVID-19 severity and survival (2020) (1522)
Anti-TNF alpha therapy of rheumatoid arthritis: what have we learned? (2001) (1277)
ROLE OF ABERRANT HLA-DR EXPRESSION AND ANTIGEN PRESENTATION IN INDUCTION OF ENDOCRINE AUTOIMMUNITY (1983) (1230)
INHIBITORY EFFECT OF TNFα ANTIBODIES ON SYNOVIAL CELL INTERLEUKIN-1 PRODUCTION IN RHEUMATOID ARTHRITIS (1989) (1152)
IRF5 promotes inflammatory macrophage polarization and TH1-TH17 responses (2011) (1073)
Anti-tumor necrosis factor ameliorates joint disease in murine collagen-induced arthritis. (1992) (1033)
Treatment of rheumatoid arthritis with chimeric monoclonal antibodies to tumor necrosis factor alpha. (1993) (871)
Excessive production of interleukin 6/B cell stimulatory factor‐2 in rheumatoid arthritis (1988) (791)
Development of anti-TNF therapy for rheumatoid arthritis (2002) (698)
Repeated therapy with monoclonal antibody to tumour necrosis factor α (cA2) in patients with rheumatoid arthritis (1994) (668)
Localization of tumor necrosis factor alpha in synovial tissues and at the cartilage-pannus junction in patients with rheumatoid arthritis. (1991) (619)
Regulation of cytokines, cytokine inhibitors, and acute-phase proteins following anti-TNF-alpha therapy in rheumatoid arthritis. (1999) (598)
The nonpsychoactive cannabis constituent cannabidiol is an oral anti-arthritic therapeutic in murine collagen-induced arthritis. (2000) (565)
Immunoregulatory role of interleukin 10 in rheumatoid arthritis (1994) (558)
Assessment of antibodies to double-stranded DNA induced in rheumatoid arthritis patients following treatment with infliximab, a monoclonal antibody to tumor necrosis factor alpha: findings in open-label and randomized placebo-controlled trials. (2000) (546)
Role of interleukin‐1β in postoperative cognitive dysfunction (2010) (525)
Tumor necrosis factor-α triggers a cytokine cascade yielding postoperative cognitive decline (2010) (481)
Autoimmunity to specific citrullinated proteins gives the first clues to the etiology of rheumatoid arthritis (2010) (463)
Resolving postoperative neuroinflammation and cognitive decline (2011) (460)
Induction of tolerance in influenza virus-immune T lymphocyte clones with synthetic peptides of influenza hemagglutinin (1983) (451)
Trials of anti-tumour necrosis factor therapy for COVID-19 are urgently needed (2020) (450)
HLA class II induction in human islet cells by interferon-γ plus tumour necrosis factor or lymphotoxin (1987) (433)
Reduction of chemokine levels and leukocyte traffic to joints by tumor necrosis factor alpha blockade in patients with rheumatoid arthritis. (2000) (428)
Epithelial cells expressing aberrant MHC class II determinants can present antigen to cloned human T cells (1984) (420)
Alarmins: awaiting a clinical response. (2012) (413)
Macrophage heterogeneity in the context of rheumatoid arthritis (2016) (405)
Regulation of monocyte IL-10 synthesis by endogenous IL-1 and TNF-alpha: role of the p38 and p42/44 mitogen-activated protein kinases. (1998) (386)
TNF alpha--a pivotal role in rheumatoid arthritis? (1992) (380)
Anti-TNF therapy: past, present and future. (2015) (371)
Modulation of angiogenic vascular endothelial growth factor by tumor necrosis factor alpha and interleukin-1 in rheumatoid arthritis. (1998) (370)
Anti-TNF biologic agents: still the therapy of choice for rheumatoid arthritis (2009) (357)
The role of macrophages in the generation of T-helper cells. II. The genetic control of the macrophage-T-cell interaction for helper cell induction with soluble antigens (1975) (356)
Increased levels of soluble tumor necrosis factor receptors in the sera and synovial fluid of patients with rheumatic diseases. (1992) (353)
Role of cytokines in rheumatoid arthritis: an education in pathophysiology and therapeutics (2008) (349)
Canonical pathway of nuclear factor kappa B activation selectively regulates proinflammatory and prothrombotic responses in human atherosclerosis. (2004) (345)
Interleukin-1 and tumour necrosis factor mRNA expression in rheumatoid arthritis: prolonged production of IL-1 alpha. (1988) (344)
Modulation of cytokine production by transforming growth factor-beta. (1989) (334)
TNF defined as a therapeutic target for rheumatoid arthritis and other autoimmune diseases (2003) (330)
Relationship between Th1/Th2 cytokine patterns and the arthritogenic response in collagen‐induced arthritis (1996) (328)
Human T-cell clones from autoimmune thyroid glands: specific recognition of autologous thyroid cells. (1985) (314)
Modulation of proinflammatory cytokine release in rheumatoid synovial membrane cell cultures. Comparison of monoclonal anti TNF-alpha antibody with the interleukin-1 receptor antagonist. (1995) (309)
Interferon-gamma induces HLA-DR expression by thyroid epithelium. (1985) (303)
Design of effective immunotherapy for human autoimmunity (2005) (290)
Interleukin-10 inhibition of the progression of established collagen-induced arthritis. (1996) (287)
Detection of interleukin 8 biological activity in synovial fluids from patients with rheumatoid arthritis and production of interleukin 8 mRNA by isolated synovial cells (1990) (284)
TNF-α promotes fracture repair by augmenting the recruitment and differentiation of muscle-derived stromal cells (2011) (278)
Efficient adenoviral infection with IkappaB alpha reveals that macrophage tumor necrosis factor alpha production in rheumatoid arthritis is NF-kappaB dependent. (1998) (274)
Effective antigen presentation by dendritic cells is NF-kappaB dependent: coordinate regulation of MHC, co-stimulatory molecules and cytokines. (2001) (271)
THE RELATIONSHIP BETWEEN ANTIGENIC STRUCTURE AND THE REQUIREMENT FOR THYMUS-DERIVED CELLS IN THE IMMUNE RESPONSE (1971) (267)
Prevention and amelioration of collagen‐induced arthritis by blockade of the CD28 co‐stimulatory pathway: requirement for both B7‐1 and B7‐2 (1996) (266)
Deactivation of vascular endothelium by monoclonal anti-tumor necrosis factor alpha antibody in rheumatoid arthritis. (1996) (261)
Raised serum vascular endothelial growth factor levels are associated with destructive change in inflammatory arthritis. (2001) (259)
Lasker Clinical Medical Research Award. TNF defined as a therapeutic target for rheumatoid arthritis and other autoimmune diseases. (2003) (256)
Chronic exposure to tumor necrosis factor (TNF) in vitro impairs the activation of T cells through the T cell receptor/CD3 complex; reversal in vivo by anti-TNF antibodies in patients with rheumatoid arthritis. (1994) (252)
Rheumatoid Arthritis (1996) (252)
Detection of cytokines at the cartilage/pannus junction in patients with rheumatoid arthritis: implications for the role of cytokines in cartilage destruction and repair. (1992) (244)
Cytokines in autoimmunity. (1992) (242)
CELL INTERACTIONS IN THE IMMUNE RESPONSE IN VITRO (1972) (241)
Control of established experimental allergic encephalomyelitis by inhibition of tumor necrosis factor (TNF) activity within the central nervous system using monoclonal antibodies and TNF receptor‐immunoglobulin fusion proteins (1994) (234)
Defining therapeutic targets by using adenovirus: blocking NF-kappaB inhibits both inflammatory and destructive mechanisms in rheumatoid synovium but spares anti-inflammatory mediators. (1999) (232)
Anti-tumor necrosis factor-alpha therapy of rheumatoid arthritis. (1997) (228)
Localization of tumor necrosis factor receptors in the synovial tissue and cartilage-pannus junction in patients with rheumatoid arthritis. Implications for local actions of tumor necrosis factor alpha. (1992) (227)
Platelet-derived interleukin 1 induces human endothelial adhesion molecule expression and cytokine production (1991) (223)
The role of cytokines in the pathogenesis of rheumatoid arthritis. (1999) (223)
Distinct pathways of LPS-induced NF-kappa B activation and cytokine production in human myeloid and nonmyeloid cells defined by selective utilization of MyD88 and Mal/TIRAP. (2004) (222)
Persistence of collagen type II-specific T-cell clones in the synovial membrane of a patient with rheumatoid arthritis. (1989) (221)
Two inhibitors of pro‐inflammatory cytokine release, interleukin‐10 and interleukin‐4, have contrasting effects on release of soluble p75 tumor necrosis factor receptor by cultured monocytes (1994) (210)
Tolerance, Enhancement and the Regulation of Interactions Between T Cells, B Cells and Macrophages (1972) (200)
Is targeting Toll‐like receptors and their signaling pathway a useful therapeutic approach to modulating cytokine‐driven inflammation? (2004) (199)
The impact of IL-1 modulation on the development of lipopolysaccharide-induced cognitive dysfunction (2010) (198)
Historical review: Cytokines as therapeutics and targets of therapeutics. (2004) (196)
Immunocytochemical characterisation of the immune reaction in the central nervous system in multiple sclerosis Possible role for microglia in lesion growth (1986) (195)
Reduction of serum matrix metalloproteinase 1 and matrix metalloproteinase 3 in rheumatoid arthritis patients following anti-tumour necrosis factor-alpha (cA2) therapy. (1997) (194)
Localization of interleukin-1 alpha, type 1 interleukin-1 receptor and interleukin-1 receptor antagonist in the synovial membrane and cartilage/pannus junction in rheumatoid arthritis. (1992) (192)
Monoclonal anti‐TNFα Antibody as a Probe of Pathogenesis and Therapy of Rheumatoid Disease (1995) (191)
Cytokine stimulation of T lymphocytes regulates their capacity to induce monocyte production of tumor necrosis factor‐α, but not interleukin‐10: Possible relevance to pathophysiology of rheumatoid arthritis (1997) (190)
Evidence that rheumatoid arthritis synovial T cells are similar to cytokine-activated T cells: involvement of phosphatidylinositol 3-kinase and nuclear factor kappaB pathways in tumor necrosis factor alpha production in rheumatoid arthritis. (2002) (188)
Synergy between anti-CD4 and anti-tumor necrosis factor in the amelioration of established collagen-induced arthritis. (1994) (188)
Selective regulation of cytokine induction by adenoviral gene transfer of IkappaBalpha into human macrophages: lipopolysaccharide-induced, but not zymosan-induced, proinflammatory cytokines are inhibited, but IL-10 is nuclear factor-kappaB independent. (1999) (186)
The Toll-like receptor adaptor proteins MyD88 and Mal/TIRAP contribute to the inflammatory and destructive processes in a human model of rheumatoid arthritis. (2007) (185)
VEGF expression in human macrophages is NF-κB-dependent: studies using adenoviruses expressing the endogenous NF-κB inhibitor IκBα and a kinase-defective form of the IκB kinase 2 (2003) (180)
Induction of the interleukin 1 receptor antagonist protein by transforming growth factor‐β (1991) (179)
The role of TNF alpha and IL-1 in rheumatoid arthritis. (2001) (179)
Cytokines and anti-cytokine biologicals in autoimmunity: present and future. (2002) (177)
Correlation between serum levels of soluble tumor necrosis factor receptor and disease activity in systemic lupus erythematosus. (1993) (176)
Immunomodulatory properties of mesenchymal stem cells: a review based on an interdisciplinary meeting held at the Kennedy Institute of Rheumatology Division, London, UK, 31 October 2005 (2007) (176)
Tolerance of T-cell clones is associated with membrane antigen changes (1983) (175)
Cytokine reference : a compendium of cytokines and other mediators of host defence (2001) (174)
Localization of tumour necrosis factor‐alpha (TNF‐α) and its receptors in normal and psoriatic skin: epidermal cells express the 55‐kD but not the 75‐kD TNF receptor (1993) (173)
Suppression of collagen-induced arthritis by continuous administration of IL-4. (1997) (172)
CELL INTERACTIONS IN THE IMMUNE RESPONSE IN VITRO (1972) (169)
NF-κB as a target for modulating inflammatory responses. (2012) (168)
Unexpected protective role for Toll-like receptor 3 in the arterial wall (2011) (168)
Treatment with Soluble VEGF Receptor Reduces Disease Severity in Murine Collagen-Induced Arthritis (2000) (167)
CELL-MEDIATED IMMUNE RESPONSE IN VITRO (1972) (166)
Longitudinal immune profiling reveals key myeloid signatures associated with COVID-19 (2020) (166)
Key differences in TLR3/poly I:C signaling and cytokine induction by human primary cells: a phenomenon absent from murine cell systems. (2007) (164)
Interleukin-2 can prevent and reverse antigen-induced unresponsiveness in cloned human T lymphocytes. (1988) (164)
Development of humanized bispecific antibodies reactive with cytotoxic lymphocytes and tumor cells overexpressing the HER2 protooncogene (1992) (164)
DBA/1 mice expressing the human TNF-alpha transgene develop a severe, erosive arthritis: characterization of the cytokine cascade and cellular composition. (1997) (163)
Collagen-induced arthritis as a model of hyperalgesia: functional and cellular analysis of the analgesic actions of tumor necrosis factor blockade. (2007) (162)
Tumor necrosis factor-alpha (TNF) triggers a cytokine cascade yielding postoperative cognitive decline (2010) (158)
Treatment of rheumatoid arthritis with chimeric monoclonal antibodies to tumor necrosis factor alpha. (2008) (156)
Interleukin‐10 rescues T cells from apoptotic cell death: association with an upregulation of Bcl‐2 (1997) (156)
Relationship Between Antigen and Antibody‐Induced Suppression of Immunity (1972) (154)
Toll-Like Receptor-2 Mediates Inflammation and Matrix Degradation in Human Atherosclerosis (2009) (153)
CELL INTERACTIONS IN THE IMMUNE RESPONSE IN VITRO (1972) (152)
Cytokine production in culture by cells isolated from the synovial membrane. (1989) (151)
Cytokine production in the rheumatoid joint: implications for treatment. (1990) (151)
T-cell-mediated signalling in immune, inflammatory and angiogenic processes: the cascade of events leading to inflammatory diseases. (2004) (147)
Detection of activated T cell products in the rheumatoid joint using cDNA probes to Interleukin-2 (IL-2) IL-2 receptor and IFN-gamma. (1988) (146)
Autoantigen recognition by thyroid-infiltrating T cells in Graves disease. (1991) (145)
Pathogenesis of arthritis: recent research progress (2001) (145)
Dynamics of proinflammatory cytokine expression in the joints of mice with collagen‐induced arthritis (CIA) (1997) (145)
Cloning of human tumor necrosis factor (TNF) receptor cDNA and expression of recombinant soluble TNF-binding protein. (1990) (144)
Many cytokines are very useful therapeutic targets in disease. (2008) (141)
Analysis of intrathyroidal cytokine production in thyroid autoimmune disease: thyroid follicular cells produce interleukin-1 alpha and interleukin-6. (1989) (141)
Specific collaboration between T and B lymphocytes across a cell impermeable membrane in vitro. (1972) (137)
Cytokines in autoimmune disorders. (1998) (137)
Role of pro-inflammatory cytokines in rheumatoid arthritis (2004) (134)
The role of macrophages in the generation of T-helper cells. I. The requirement for macrophages in helper cell induction and characteristics of the macrophage-T cell interaction. (1975) (133)
T-T interactions in the induction of suppressor and helper T cells: analysis of membrane phenotype of precursor and amplifier cells (1977) (133)
INDUCTION OF IMMUNITY AND TOLERANCE IN VITRO BY HAPTEN PROTEIN CONJUGATES (1972) (133)
Paradoxical effects of a synthetic metalloproteinase inhibitor that blocks both p55 and p75 TNF receptor shedding and TNF alpha processing in RA synovial membrane cell cultures. (1996) (132)
Role of NFκB in antigen presentation and development of regulatory T cells elucidated by treatment of dendritic cells with the proteasome inhibitor PSI (2001) (131)
Suppression of TNF-alpha expression, inhibition of Th1 activity, and amelioration of collagen-induced arthritis by rolipram. (1997) (130)
Apremilast, a novel PDE4 inhibitor, inhibits spontaneous production of tumour necrosis factor-alpha from human rheumatoid synovial cells and ameliorates experimental arthritis (2010) (130)
Contact with T cells modulates monocyte IL-10 production: role of T cell membrane TNF-alpha. (1997) (130)
T-cell lines producing antigen-specific suppressor factor (1978) (129)
Dendritic cells induce T cell proliferation to synthetic antigens under Ir gene control (1980) (129)
High level of interleukin-10 production by the activated T cell population within the rheumatoid synovial membrane. (1995) (129)
CELL INTERACTIONS IN THE IMMUNE RESPONSE IN VITRO (1972) (128)
Beneficial effects of tumour necrosis factor‐alpha (TNF‐α) blockade in rheumatoid arthritis (RA) (1995) (127)
A Novel Mechanism for TNF-α Regulation by p38 MAPK: Involvement of NF-κB with Implications for Therapy in Rheumatoid Arthritis1 (2004) (127)
A novel synthetic, nonpsychoactive cannabinoid acid (HU-320) with antiinflammatory properties in murine collagen-induced arthritis. (2004) (126)
Cytokine expression in chronic inflammatory disease. (1995) (125)
The role of macrophages in the generation of T helper cells. III. Influence of macrophage‐derived factors in helper cell induction (1975) (124)
Treatmentof murine osteoarthritis withTrkAd5 reveals a pivotal rolefor nerve growth factor in non-inflammatory joint pain (2010) (124)
ANTIBODY-MEDIATED SUPPRESSION OF THE IMMUNE RESPONSE IN VITRO (1970) (123)
Essential requirement for major histocompatibility complex recognition in T-cell tolerance induction (1984) (120)
Unraveling the signaling pathways promoting fibrosis in Dupuytren's disease reveals TNF as a therapeutic target (2013) (120)
Developments in therapy with monoclonal antibodies and related proteins (2017) (120)
IRF5 controls both acute and chronic inflammation (2015) (119)
Role of macrophages in the generation of T helper cells. IV. Nature of genetically related factor derived from macrophages incubated with soluble antigens (1976) (118)
The beta2-adrenergic agonist salbutamol is a potent suppressor of established collagen-induced arthritis: mechanisms of action. (1999) (116)
TNF defined as a therapeutic target for rheumatoid arthritis and other autoimmune diseases (2003) (115)
Collagen-induced arthritis in C57BL/6 mice is associated with a robust and sustained T-cell response to type II collagen (2007) (115)
How does infliximab work in rheumatoid arthritis? (2002) (113)
Important immunoregulatory role of interleukin-11 in the inflammatory process in rheumatoid arthritis. (1998) (111)
Validation of the interleukin‐10 knockout mouse model of colitis: antitumour necrosis factor‐antibodies suppress the progression of colitis (2003) (110)
ANTIBODY-MEDIATED SUPPRESSION OF THE IMMUNE RESPONSE IN VITRO (1970) (109)
Successful therapy of collagen-induced arthritis with TNF receptor-IgG fusion protein and combination with anti-CD4. (1995) (109)
A human suppressor T cell clone which recognizes an autologous helper T cell clone (1982) (109)
Regulation of pain sensitivity in experimental osteoarthritis by the endogenous peripheral opioid system. (2008) (109)
Evaluation of TNF-α and IL-1 Blockade in Collagen-Induced Arthritis and Comparison with Combined Anti-TNF-α/Anti-CD4 Therapy1 (2000) (107)
Cell-mediated immune response in vitro. II. The role of thymus and thymus-derived lymphocytes. (1972) (106)
Role of macrophages in in vitro induction of T-helper cells (1975) (106)
Accumulating evidence suggests anti-TNF therapy needs to be given trial priority in COVID-19 treatment (2020) (105)
Differential expression and regulation of MHC products in the endocrine and exocrine cells of the human pancreas. (1986) (105)
Anti‐IL‐12 and anti‐TNF antibodies synergistically suppress the progression of murine collagen‐induced arthritis (1999) (104)
IL-10 inhibits transcription elongation of the human TNF gene in primary macrophages (2010) (104)
Anti-TNF Therapy, from Rationale to Standard of Care: What Lessons Has It Taught Us? (2010) (103)
T cells expressing gamma delta chain receptors in rheumatoid arthritis. (1988) (101)
Adenoviral delivery of soluble VEGF receptor 1 (sFlt-1) abrogates disease activity in murine collagen-induced arthritis (2003) (101)
MONOSPECIFICITY OF BONE MARROW-DERIVED LYMPHOCYTES (1973) (101)
Selective Tumor Necrosis Factor Receptor I Blockade Is Antiinflammatory and Reveals Immunoregulatory Role of Tumor Necrosis Factor Receptor II in Collagen‐Induced Arthritis (2014) (99)
Anti-TNF therapy: where have we got to in 2005? (2005) (99)
Cytokine gene therapy in experimental allergic encephalomyelitis by injection of plasmid DNA-cationic liposome complex into the central nervous system. (1998) (99)
Different Therapeutic Outcomes in Experimental Allergic Encephalomyelitis Dependant Upon the Mode of Delivery of IL-10: A Comparison of the Effects of Protein, Adenoviral or Retroviral IL-10 Delivery into the Central Nervous System1 (2001) (98)
Different Ly antigen phenotypes of in vitro induced helper and suppressor cells (1975) (98)
Are CD4+ Th1 cells pro-inflammatory or anti-inflammatory? The ratio of IL-10 to IFN-gamma or IL-2 determines their function. (1995) (98)
The distribution of interleukin-2 receptor bearing lymphocytes in multiple sclerosis: evidence for a key role of activated lymphocytes. (1985) (97)
Enhanced expression of tumor necrosis factor receptor mRNA and protein in mononuclear cells isolated from rheumatoid arthritis synovial joints (1992) (97)
Detection of transforming growth factor‐beta in rheumatoid arthritis synovial tissue: lack of effect on spontaneous cytokine production in joint cell cultures (1990) (97)
Transforming growth factor‐β1 in rheumatoid synovial membrane and cartilage pannus junction (1991) (96)
Inhibitors of TLR8 Reduce TNF Production from Human Rheumatoid Synovial Membrane Cultures1 (2008) (95)
Cytokine inhibitors in rheumatoid arthritis and other autoimmune diseases. (2007) (95)
Functional expression of HLA-DP genes transfected into mouse fibroblasts (1985) (93)
Human T cells from autoimmune and normal individuals can produce tumor necrosis factor (1987) (93)
Therapeutic antibodies elicited by immunization against TNF-α (1999) (91)
Cytokine Assays: Role in Evaluation of the Pathogenesis of Autoimmunity (1991) (91)
The Potential for Repurposing Anti-TNF as a Therapy for the Treatment of COVID-19 (2020) (91)
Low-dose TNF augments fracture healing in normal and osteoporotic bone by up-regulating the innate immune response (2015) (91)
Separation of suppressor and killer T cells by surface phenotype (1976) (89)
Advanced glycation end products upregulate angiogenic and pro-inflammatory cytokine production in human monocyte/macrophages. (2004) (87)
Cytokine expression in rheumatoid arthritis. (1991) (87)
An inflammatory cytokine signature helps predict COVID-19 severity and death (2020) (86)
Anaemia of chronic disease in rheumatoid arthritis: in vivo effects of tumour necrosis factor alpha blockade. (1997) (86)
Transforming growth factor beta induces the production of interleukin 6 by human peripheral blood mononuclear cells. (1990) (86)
TNFα Is an Effective Therapeutic Target for Rheumatoid Arthritis a (1995) (85)
Discovery of TNF-alpha as a therapeutic target in rheumatoid arthritis: preclinical and clinical studies. (2002) (85)
Suppressor-cell induction in vitro. IV. Target of antigen-specific suppressor factor and its genetic relationships (1978) (85)
Suppressor cell induction in vitro. II. Cellular requirements of suppressor cell induction (1976) (85)
Paradoxical effects of adenovirus-mediated blockade of TNF activity in murine collagen-induced arthritis. (1999) (84)
NF-κB-Inducing Kinase Is Dispensable for Activation of NF-κB in Inflammatory Settings but Essential for Lymphotoxin β Receptor Activation of NF-κB in Primary Human Fibroblasts1 (2001) (84)
Production of interleukin-1 and interleukin-6 by human keratinocytes and squamous cell carcinoma cell lines. (1991) (83)
Critical role of CD28/B7 costimulation in the development of human Th2 cytokine-producing cells. (1995) (83)
Cell-mediated immune response in vitro. I. A new in vitro system for the generation of cell-mediated cytotoxic activity. (1972) (83)
TNF-alpha in rheumatoid arthritis and prospects of anti-TNF therapy. (1993) (83)
Longitudinal study of soluble adhesion molecules in multiple sclerosis (1997) (82)
Regulation of expression of human IL-1 alpha and IL-1 beta genes. (1989) (82)
Identification and Characterization of 4-[[4-(2-Butynyloxy)phenyl]sulfonyl]-N-hydroxy-2,2-dimethyl-(3S)thiomorpholinecarboxamide (TMI-1), a Novel Dual Tumor Necrosis Factor-α-Converting Enzyme/Matrix Metalloprotease Inhibitor for the Treatment of Rheumatoid Arthritis (2004) (82)
Vascular endothelial growth factor signalling in endothelial cell survival: a role for NFkappaB. (2006) (81)
Anti-tumour necrosis factor specific antibody (infliximab) treatment provides insights into the pathophysiology of rheumatoid arthritis (1999) (81)
TREM-1 expression is increased in the synovium of rheumatoid arthritis patients and induces the expression of pro-inflammatory cytokines. (2009) (81)
Coordinate expansion of 'fetal type' lymphocytes (TCR gamma delta+T and CD5+B) in rheumatoid arthritis and primary Sjögren's syndrome. (1989) (80)
Putative role for interleukin‐7 in the maintenance of the recirculating naive CD4+ T‐cell pool (1999) (80)
B Cell heterogeneity - difference in the size of B lymphocytes responding to T dependent and T independent antigens. (1975) (80)
Fully reduced HMGB1 accelerates the regeneration of multiple tissues by transitioning stem cells to GAlert (2018) (80)
Inhibition of transfer of collagen-induced arthritis into SCID mice by ex vivo infection of spleen cells with retroviruses expressing soluble tumor necrosis factor receptor. (1995) (79)
Is NF-κB a useful therapeutic target in rheumatoid arthritis? (2002) (79)
Interleukin 4 induces interleukin 6 production by endothelial cells: Synergy with interferon‐γ (1991) (79)
Indoleamine 2,3-dioxygenase-1 is protective in atherosclerosis and its metabolites provide new opportunities for drug development (2015) (79)
Rac mediates TNF-induced cytokine production via modulation of NF-kappaB. (2008) (78)
Heterogeneous requirement of IkappaB kinase 2 for inflammatory cytokine and matrix metalloproteinase production in rheumatoid arthritis: implications for therapy. (2003) (78)
Effective adenoviral transfer of IkappaBalpha into human fibroblasts and chondrosarcoma cells reveals that the induction of matrix metalloproteinases and proinflammatory cytokines is nuclear factor-kappaB dependent. (2000) (77)
The transfer of a laboratory based hypothesis to a clinically useful therapy: the development of anti-TNF therapy of rheumatoid arthritis. (2004) (77)
Molecular therapeutic targets in rheumatoid arthritis (2005) (77)
Inhibition of p38 mitogen-activated protein kinase is effective in the treatment of experimental crescentic glomerulonephritis and suppresses monocyte chemoattractant protein-1 but not IL-1beta or IL-6. (2007) (75)
Production of TGF-alpha and TGF-beta by cultured keratinocytes, skin and oral squamous cell carcinomas--potential autocrine regulation of normal and malignant epithelial cell proliferation. (1989) (75)
Adenovirus-mediated gene transfer of CTLA-4Ig fusion protein in the suppression of experimental autoimmune arthritis. (2000) (74)
Expression of intercellular adhesion molecule-1 and lymphocyte function-associated antigen-3 on human thyroid epithelial cells in Graves' and Hashimoto's diseases. (1990) (74)
Suppressor cell induction in vitro. I. Kinetics of induction of antigen‐specific suppressor cells (1976) (74)
Role of C3 in in vitro lymphocyte cooperation (1974) (74)
c-erbB-2 expression in different histological types of invasive breast carcinoma. (1991) (74)
Daily urinary neopterin excretion as an immunological marker of disease activity in multiple sclerosis. (1997) (74)
MS: a localized immune disease of the central nervous system. (1989) (73)
The requirement for macrophages in the secondary immune response to antigens of small and large size in vitro. (1971) (72)
Ikappa B kinase 2 but not NF-kappa B-inducing kinase is essential for effective DC antigen presentation in the allogeneic mixed lymphocyte reaction. (2003) (72)
CD44 involvement in experimental collagen-induced arthritis (CIA). (1999) (72)
Adenoviral gene transfer of the endogenous inhibitor IkappaBalpha into human osteoarthritis synovial fibroblasts demonstrates that several matrix metalloproteinases and aggrecanases are nuclear factor-kappaB-dependent. (2007) (71)
Molecular Profile of Peripheral Blood Mononuclear Cells from Patients with Rheumatoid Arthritis (2007) (71)
Adenoviral gene transfer into osteoarthritis synovial cells using the endogenous inhibitor IkappaBalpha reveals that most, but not all, inflammatory and destructive mediators are NFkappaB dependent. (2006) (71)
Interleukin 7 is a growth factor for mature human T cells (1990) (70)
Soluble E-selectin in multiple sclerosis: raised concentrations in patients with primary progressive disease. (1996) (69)
TNFα‐induced macrophage chemokine secretion is more dependent on NF‐κB expression than lipopolysaccharides‐induced macrophage chemokine secretion (2002) (69)
Cell interactions in the immune response in vitro. VI. Mediation by T cell surface monomeric IgM. (1973) (68)
Induction of immunity and tolerance in vitro by hapten protein conjugates. II. Carrier independence of the response to dinitrophenylated polymerized flagellin (1972) (67)
Cartilage destruction and bone erosion in arthritis: the role of tumour necrosis factor α (2000) (67)
Is there a role for TNF-alpha in anti-neutrophil cytoplasmic antibody-associated vasculitis? Lessons from other chronic inflammatory diseases. (2006) (67)
In vitro studies on H‐2‐linked unresponsiveness to synthetic polypeptides (1977) (67)
Activation of NF-κB by the intracellular expression of NF-κB-inducing kinase acts as a powerful vaccine adjuvant (2006) (67)
T cell‐mediated signaling to vascular endothelium: induction of cytokines, chemokines, and tissue factor (2002) (67)
Stimulation of the α7 Nicotinic Acetylcholine Receptor Protects against Neuroinflammation after Tibia Fracture and Endotoxemia in Mice (2014) (66)
Functional activities of receptors for tumor necrosis factor-alpha on human vascular endothelial cells. (1994) (66)
Detection of interleukin‐6 and interleukin‐1 production in human thyroid epithelial cells by non‐radioactive in situ hybridization and immunohistochemical methods (1991) (66)
Nonsteroidal Anti-Inflammatory Drugs Increase TNF Production in Rheumatoid Synovial Membrane Cultures and Whole Blood (2010) (66)
TNF blockade in rheumatoid arthritis: Implications for therapy and pathogenesis (1997) (65)
Human T cell clones present antigen. (1989) (65)
Induction of immunity and tolerance to the dinitrophenyl determinant in vitro. (1971) (65)
Therapeutic antibodies elicited by immunization against TNF-alpha. (1999) (65)
Direct triggering of B lymphocytes by insolubilized antigen (1974) (64)
Interleukin 7 (murine pre‐B cell growth factor/lymphopoietin 1) stimulates thymocyte growth: regulation by transforming growth factor beta (1989) (64)
Neutralizing IL‐21 and IL‐15 Inhibits Pro‐inflammatory Cytokine Production in Rheumatoid Arthritis (2008) (64)
Cell interactions in the immune response in vitro. I. Metabolic activities of T cells in a collaborative antibody response (1972) (64)
Human self-reactive T cell clones expressing identical T cell receptor beta chains differ in their ability to recognize a cryptic self-epitope (1996) (64)
The toll-like receptor-nuclear factor kappaB pathway in rheumatoid arthritis. (2005) (64)
Impact of VIP and cAMP on the regulation of TNF-α and IL-10 production: implications for rheumatoid arthritis (2003) (64)
Functional activities of receptors for tumor necrosis factor-alpha on human vascular endothelial cells (1994) (63)
Suppressor cell induction in vitro (1977) (63)
Tumour necrosis factor alpha as a therapeutic target for immune-mediated inflammatory diseases. (2004) (62)
Functional comparisons of different tumour necrosis factor receptor/IgG fusion proteins. (1995) (62)
Cytokine receptors: structure and signal transduction (1992) (61)
Detection of cytokines at the site of tuberculin‐induced delayed‐type hypersensitivity in man (1992) (61)
Enhancement of thyrocyte HLA class II expression by thyroid stimulating hormone. (1987) (61)
Evaluation of the role of cytokines in autoimmune disease: the importance of TNF alpha in rheumatoid arthritis. (1992) (61)
Cytokine blockade in rheumatoid arthritis. (2001) (60)
Human macrophages induced in vitroby macrophage colony‐stimulating factor are deficient in IL‐12 production (1998) (60)
DO CD4-POSITIVE CYTOTOXIC T CELLS DAMAGE ISLET β CELLS IN TYPE 1 DIABETES? (1988) (60)
Chronic relapsing homologous collagen-induced arthritis in DBA/1 mice as a model for testing disease-modifying and remission-inducing therapies. (2001) (59)
The anti-allergic drug, N-(3',4'-dimethoxycinnamonyl) anthranilic acid, exhibits potent anti-inflammatory and analgesic properties in arthritis. (2007) (59)
Inhibition of histone H3K27 demethylases selectively modulates inflammatory phenotypes of natural killer cells (2018) (58)
SIGIRR/TIR-8 is an inhibitor of Toll-like receptor signaling in primary human cells and regulates inflammation in models of rheumatoid arthritis. (2010) (58)
The angiogenesis inhibitor protease-activated kringles 1–5 reduces the severity of murine collagen-induced arthritis (2002) (58)
Translating molecular insights in autoimmunity into effective therapy. (2009) (57)
Investigating the role of the interleukin-23/-17A axis in rheumatoid arthritis (2009) (55)
Monoclonal antibodies in immune and inflammatory diseases. (2002) (55)
Effective targeting of the tumor microenvironment for cancer therapy. (2012) (55)
CD200-Fc, a novel antiarthritic biologic agent that targets proinflammatory cytokine expression in the joints of mice with collagen-induced arthritis. (2008) (55)
CD40 ligation induces macrophage IL-10 and TNF-alpha production: differential use of the PI3K and p42/44 MAPK-pathways. (2001) (54)
Resistance to regulatory T cell-mediated suppression in rheumatoid arthritis can be bypassed by ectopic foxp3 expression in pathogenic synovial T cells (2011) (54)
Soluble TNF receptor production by activated T lymphocytes: differential effects of acute and chronic exposure to TNF. (1995) (54)
Increased production of intracellular interleukin-1 receptor antagonist type I in the synovium of mice with collagen-induced arthritis: a possible role in the resolution of arthritis. (2001) (54)
TNF Inhibitors are Produced Spontaneously by Rheumatoid and Osteoarthritic Synovial Joint Cell Cultures: Evidence of Feedback Control of TNF Action (1995) (54)
Local gene therapy with CTLA4‐immunoglobulin fusion protein in experimental allergic encephalomyelitis (1998) (54)
p55 and p75 tumor necrosis factor receptors are expressed and mediate common functions in synovial fibroblasts and other fibroblasts. (1994) (53)
Anti-TNFalpha therapy of rheumatoid arthritis: what can we learn about chronic disease? (2004) (52)
Humoral and cell mediated responses in vitro of spleen cells from mice with thymic aplasia (nude mice). (1972) (52)
Heterogeneity of T cell receptor idiotypes in rheumatoid arthritis. (1988) (52)
TNF alpha as a therapeutic target in rheumatoid arthritis. (1994) (52)
Differential effects of Th1 versus Th2 cytokines in combination with hypoxia on HIFs and angiogenesis in RA (2012) (50)
Resting CD4+ effector memory T cells are precursors of bystander-activated effectors: a surrogate model of rheumatoid arthritis synovial T-cell function (2008) (50)
Induction of specific helper cells in vitro. (1973) (50)
The cellular pathway of antigen presentation: biochemical and functional analysis of antigen processing in dendritic cells and macrophages. (1986) (50)
Efficient adenoviral infection with I k B a reveals that macrophage tumor necrosis factor a production in rheumatoid arthritis is NF- k B dependent (1998) (49)
IL-17 induces hyperalgesia via TNF-dependent neutrophil infiltration (2011) (49)
Lymphotoxin acts as an autocrine growth factor for Epstein‐Barr virus‐transformed B cells and differentiated Burkitt lymphoma cell lines (1994) (49)
Autocrine and paracrine regulation of human T cell IL-10 production. (1997) (49)
Interleukin-6 localisation in the synovial membrane in rheumatoid arthritis (1991) (49)
Mechanism of immune complex‐mediated damage: induction of interleukin 1 by immune complexes and synergy with interferon‐γ and tumor necrosis factor‐α (1989) (49)
Granulocyte-macrophage colony stimulating factor induces both HLA-DR expression and cytokine production by human monocytes. (1990) (48)
INDUCTION OF IMMUNITY AND TOLERANCE IN VITRO BY HAPTEN PROTEIN CONJUGATES (1972) (48)
Activation of NF-kappaB by the intracellular expression of NF-kappaB-inducing kinase acts as a powerful vaccine adjuvant. (2006) (47)
Novel splice variants derived from the receptor tyrosine kinase superfamily are potential therapeutics for rheumatoid arthritis (2008) (47)
Nonphagocytic dendritic cells are effective accessory cells for anti-mycobacterial responses in vitro. (1985) (47)
Regulation of macrophage accessory cell activity by mycobacteria. II. In vitro inhibition of Ia expression by Mycobacterium microti. (1986) (47)
Interleukin‐4 inhibits χ light chain expression and NFχB activation but not IχBα degradation in 70Z/3 murine pre‐B cells (1995) (46)
Gene Therapy for Chronic Relapsing Experimental Allergic Encephalomyelitis Using Cells Expressing a Novel Soluble p75 Dimeric TNF Receptor1 (2000) (46)
Identification of thyroid stimulating hormone receptor-specific T cells in Graves' disease thyroid using autoantigen-transfected Epstein-Barr virus-transformed B cell lines. (1995) (46)
COVID-19 therapeutics: Challenges and directions for the future (2022) (46)
TNF receptor 2 signaling prevents DNA methylation at the Foxp3 promoter and prevents pathogenic conversion of regulatory T cells (2019) (46)
Murine IL-10 Gene Transfer Inhibits Established Collagen-Induced Arthritis and Reduces Adenovirus-Mediated Inflammatory Responses in Mouse Liver1 (2001) (46)
Preclinical target validation using patient-derived cells (2015) (46)
What have we learnt from targeted anti-TNF therapy? (2009) (45)
Definition of a population of CD4-8- T cells that express the alpha beta T-cell receptor and respond to interleukins 2, 3, and 4. (1989) (45)
Antibody-mediated suppression of the immune response in vitro. 3. Low zone tolerance in vitro. (1971) (45)
RelB/p50 regulates TNF production in LPS-stimulated dendritic cells and macrophages. (2013) (45)
T cell suppression in vitro. II. Nature of specific suppressive factor (1974) (44)
Nature of T-cell macrophage interaction in helper-cell induction in vitro. II. Two stages of T-helper-cell differentiation analyzed in irradiation and allophenic chimeras (1979) (44)
Histone H3K27me3 demethylases regulate human Th17 cell development and effector functions by impacting on metabolism (2019) (44)
Blockade of NKG2D ameliorates disease in mice with collagen-induced arthritis: a potential pathogenic role in chronic inflammatory arthritis. (2011) (44)
Cytokine-stimulated T cells induce macrophage IL-10 production dependent on phosphatidylinositol 3-kinase and p70S6K: implications for rheumatoid arthritis (2001) (44)
Detection of in vivo production of tumour necrosis factor-alpha by human thyroid epithelial cells. (1992) (44)
NF-kappaB-inducing kinase is dispensable for activation of NF-kappaB in inflammatory settings but essential for lymphotoxin beta receptor activation of NF-kappaB in primary human fibroblasts. (2001) (43)
Perspectives From Masters in Rheumatology and Autoimmunity: Can We Get Closer to a Cure for Rheumatoid Arthritis? (2015) (43)
Interleukin‐7 activates human naive CD4+ cells and primes for interleukin‐4 production (1997) (42)
The therapeutic activity of low-dose irradiation on experimental arthritis depends on the induction of endogenous regulatory T cell activity (2010) (42)
Efficient Propagation and Cloning of Human T Cells in the Absence of Antigen by Means of OKT3, Interleukin 2, and Antigen‐Presenting Cells (1988) (42)
The rationale for the current boom in anti-TNFα treatment. Is there an effective means to define therapeutic targets for drugs that provide all the benefits of anti-TNFα and minimise hazards? (1999) (42)
Selective Use of TRAM in Lipopolysaccharide (LPS) and Lipoteichoic Acid (LTA) Induced NF-κB Activation and Cytokine Production in Primary Human Cells: TRAM Is an Adaptor for LPS and LTA Signaling1 (2007) (41)
Role of epitope density in the induction of immunity and tolerance with thymus‐independent antigens. I. Studies with 2,4‐dinitrophenyl conjugates in vitro (1975) (41)
Pathogenetic relevance of HLA class II expressing thyroid follicular cells in nontoxic Goiter and in Graves' disease. (1988) (40)
Mechanisms at the cellular level during induction of high zone tolerance in vitro. (1972) (40)
Reduction of cPLA2α overexpression: An efficient anti‐inflammatory therapy for collagen‐induced arthritis (2008) (40)
Increased urinary nitric oxide metabolites in patients with multiple sclerosis correlates with early and relapsing disease (1999) (40)
The Activity of Immunoregulatory T Cells Mediating Active Tolerance Is Potentiated in Nonobese Diabetic Mice by an IL-4-Based Retroviral Gene Therapy1 (2001) (39)
Cytokine expression and networks in rheumatoid arthritis: rationale for anti-TNF alpha antibody therapy and its mechanism of action. (1995) (39)
The majority of the activated T cells in the blood of insulin-dependent diabetes mellitus (IDDM) patients are CD4+. (1988) (39)
Cytophilic properties of surface immunoglobulin of thymus-derived lymphocytes. (1974) (38)
Effect of recombinant cytokines on glycolysis and fructose 2,6-bisphosphate in rheumatoid synovial cells in vitro. (1988) (38)
Down-regulation of Th1-mediated pathology in experimental arthritis by stimulation of the Th2 arm of the immune response. (2003) (38)
Therapeutic actions of cyclosporine and anti-tumor necrosis factor alpha in collagen-induced arthritis and the effect of combination therapy. (1998) (38)
Serological analysis of antigen‐specific helper factors specific for poly‐L(Tyr, Glu)‐poly‐DLAla–poly‐LLys [(T, G)‐A–L] and LGlu60‐LAla30‐LTyr10 (GAT) (1979) (38)
Updated consensus statement on tumour necrosis factor blocking agents for the treatment of rheumatoid arthritis (May 2000) (2000) (38)
T cell suppression in vitro. I. Role in regulation of antibody responses (1974) (37)
HLA‐D/DR Expression on Epithelial Cells: The Finger on the Trigger? a (1986) (37)
Contrasting effects of interferon gamma and interleukin 4 on responses of human vascular endothelial cells to tumour necrosis factor alpha. (1992) (37)
Interferons and autoimmunity. (1987) (37)
Dynamic aspects of antigen binding to B cells in immune induction. (1972) (36)
Inappropriate major histocompatibility complex class II expression by thyroid follicular cells in thyroid autoimmune disease and by pancreatic beta cells in type I diabetes. (1986) (36)
Emerging approaches for the therapy of autoimmune and chronic inflammatory disease. (2004) (36)
Immune response (Ir) genes expressed at macrophage–B lymphocyte interactions (1978) (35)
TNF alpha blockade in rheumatoid arthritis: rationale, clinical outcomes and mechanisms of action. (1995) (35)
TNFalpha-induced macrophage chemokine secretion is more dependent on NF-kappaB expression than lipopolysaccharides-induced macrophage chemokine secretion. (2002) (35)
Selective activation of T cells in newly diagnosed insulin‐dependent diabetic patients: evidence for heterogeneity of T cell receptor usage (1991) (35)
Differential regulation of tumour necrosis factor receptors (TNF-R) by IL-4; upregulation of P55 and P75 TNF-R on synovial joint mononuclear cells. (1993) (35)
OX40L blockade is therapeutic in arthritis, despite promoting osteoclastogenesis (2014) (35)
IL-4-induced eosinophil accumulation in rat skin is dependent on endogenous TNF-alpha and alpha 4 integrin/VCAM-1 adhesion pathways. (1998) (35)
TNFR2 increases the sensitivity of ligand-induced activation of the p38 MAPK and NF-κB pathways and signals TRAF2 protein degradation in macrophages. (2014) (35)
The importance of T cell interactions with macrophages in rheumatoid cytokine production. (2006) (35)
Alveolar macrophages and T cells from sarcoid, but not normal lung, are permissive to adenovirus infection and allow analysis of NF-kappa b-dependent signaling pathways. (2001) (35)
Tumor Necrosis Factor α-Induced Eosinophil Accumulation in Rat Skin Is Dependent on α4 Integrin/Vascular Cell Adhesion Molecule-1 Adhesion Pathways (1997) (35)
Anti-Tumour Necrosis Factor Therapy for Dupuytren's Disease: A Randomised Dose Response Proof of Concept Phase 2a Clinical Trial (2018) (35)
Selective blockade of tumor necrosis factor receptor I inhibits proinflammatory cytokine and chemokine production in human rheumatoid arthritis synovial membrane cell cultures. (2013) (35)
Antibody-mediated suppression of the immune response in vitro. IV. The effect of antibody fragments. (1972) (34)
Role of Tyrosine Kinase Enzymes in TNF‐α and IL‐1 Induced Expression of ICAM‐1 and VCAM‐1 on Human Umbilical Vein Endothelial Cells (1997) (34)
IL-10 enhances expression of the IL-2 receptor alpha chain on T cells. (1994) (34)
Nature of T cell‐macrophage interaction in helper cell induction in vitro I. Evidence for genetic restriction of T cell‐macrophage interactions prior to T cell priming (1978) (34)
Antigen‐specific T cell unresponsiveness in cloned helper T cells mediated via the CD2 or CD3/Ti receptor pathways (1987) (33)
The mechanism of antigenic competition. i. the macrophage as a site of a reversible block of t‐b lymphocyte collaboration (1973) (33)
Biological insights from clinical trials with anti-TNF therapy (2004) (33)
Towards an understanding of the role of DNA methylation in rheumatoid arthritis: therapeutic and diagnostic implications (2015) (33)
T cell clones from a Sjögren's syndrome salivary gland biopsy produce high levels of IL‐10 (1996) (33)
Long-term human T-helper lines producing specific helper factor reactive to influenza virus (1981) (33)
CD4+ T‐Cell Clones from Autoimmune Thyroid Tissue Cannot be Classified According to their Lymphokine Production (1990) (32)
TNF autovaccination induces self anti-TNF antibodies and inhibits metastasis in a murine melanoma model (2004) (32)
Structural characteristics of antigen-specific suppressor factors: definition of 'constant' region and 'variable' region determinants. (1979) (32)
Antigen Presentation by Murine Dendritic Cells is Nuclear Factor‐kappa B Dependent Both In Vitro and In Vivo (2003) (32)
Balance between activating NKG2D, DNAM‐1, NKp44 and NKp46 and inhibitory CD94/NKG2A receptors determine natural killer degranulation towards rheumatoid arthritis synovial fibroblasts (2014) (32)
Identifying collagen VI as a target of fibrotic diseases regulated by CREBBP/EP300 (2020) (32)
Modulation of the IL‐1 cytokine network in keratinocytes by intracellular IL‐1α and IL‐1 receptor antagonist (1995) (32)
Targeting TNF alpha for the therapy of rheumatoid arthritis. (1994) (31)
Mechanisms of B-cell tolerance. (1976) (31)
Cloning, expression and cross‐linking analysis of the murine p55 tumor necrosis factor receptor (1991) (31)
HER2 (c-erbB-2) oncoprotein expression in colorectal adenocarcinoma: an immunohistological study using three different antibodies. (1992) (31)
Two-gene control of T-helper cell induction (1976) (31)
Derivation of ganglioside-specific T cell lines of suppressor or helper phenotype from cerebrospinal fluid of multiple sclerosis patients (1986) (30)
SECONDARY CYTOTOXIC ALLOGRAFT RESPONSES IN VITRO: III. THE IMMUNOGENICITY OF ALLOGENEIC MEMBRANE FRAGMENTS (1976) (30)
The Cytokine Network in Rheumatoid Arthritis: Definition of TNFα as a Therapeutic Target (1996) (29)
Gene therapy of rheumatoid arthritis via cytokine regulation: future perspectives. (1995) (29)
Route of monocyte differentiation determines their cytokine production profile: CD40 ligation induces interleukin 10 expression. (2000) (29)
Effect of cytokines on HLA-DR and IL-1 production by a monocytic tumour, THP-1. (1989) (29)
Current concepts of the antibody response: heterogeneity of lymphoid cells, interactions, and factors. (1977) (28)
What is the mechanism of action of anti-tumour necrosis factor-alpha antibody in rheumatoid arthritis? (1996) (28)
T–T interaction in the generation of helper cells in vitro (1975) (27)
Comparison of patterns of expression of tumour necrosis factor, lymphotoxin and interleukin-6 mRNA. (1988) (27)
Anti-tumor necrosis factor alpha therapy of rheumatoid arthritis. Mechanism of action. (1997) (27)
A comparative study into the mechanisms of action of anti-tumor necrosis factor alpha, anti-CD4, and combined anti-tumor necrosis factor alpha/anti-CD4 treatment in early collagen-induced arthritis. (2000) (27)
Epidermal growth factor and transforming growth factor-alpha suppress HLA class II induction in human thyroid epithelial cells. (1990) (27)
Expression of alloantigens LY-5 and LY-6 on cytotoxic effector cells. (1977) (27)
Role of Antigen Structure in the Discrimination between Tolerance and Immunity by B Cells (1975) (27)
P‐selectin glycoprotein ligand 1 therapy ameliorates established collagen‐induced arthritis in DBA/1 mice partly through the suppression of tumour necrosis factor (2004) (27)
Similarities in the mechanisms of action of pulse corticosteroids and anti-tumor necrosis factor ? therapy in rheumatoid arthritis (1998) (26)
Inhibition of T cell proliferation by antibodies to synthetic peptides (1984) (26)
Tolerance in T-cell clones. (1985) (26)
Lack of requirement for cell cooperation in the antibody response to DNP conjugated to levan. (1975) (26)
Investigation of nuclear factor‐κB inhibitors and interleukin‐10 as regulators of inflammatory signalling in human adipocytes (2010) (26)
Analysis of T-cell receptor usage in activated T-cell clones from Hashimoto's thyroiditis and Graves' disease. (1989) (26)
Enrichment of antigen-specific helper and suppressor T cells (1976) (25)
Synergism of glucocorticoids with granulocyte macrophage colony stimulating factor (GM-CSF) but not interferon gamma (IFN-gamma) or interleukin-4 (IL-4) on induction of HLA class II expression on human monocytes. (1992) (25)
Human T Cell Clones (1985) (25)
POLYCLONAL MITOGENS AND THE NATURE OF B LYMPHOCYTE ACTIVATION MECHANISMS (1974) (25)
T cell activation and antigen presentation in human thyroid autoimmunity. (1992) (24)
Tolerance induction to a hapten protein conjugate in vivo: Are suppressor T cells involved (1974) (24)
Could toll-like receptors provide a missing link in chronic inflammation in rheumatoid arthritis? Lessons from a study on human rheumatoid tissue (2007) (24)
Anti-TNF Therapy. (2016) (23)
The role of receptors for tumour necrosis factor-alpha in the induction of human polymorphonuclear neutrophil chemiluminescence. (1996) (23)
Regulation of HLA class II expression and its role in autoimmune disease. (1987) (23)
Adenoviral transgene delivery provides an approach to identifying important molecular processes in inflammation: evidence for heterogenecity in the requirement for NFκB in tumour necrosis factor production (2000) (23)
Effects of cyclosporin A on expression of IL-2 and IL-2 receptors in normal and multiple sclerosis patients. (1987) (23)
Transfection of thyroid autoantigens into EBV-transformed B cell lines. Recognition by Graves' disease thyroid T cells. (1994) (23)
T cells and lymphokines. (1989) (22)
Molecular mechanisms involved in human autoimmune diseases: relevance of chronic antigen presentation. Class II expression and cytokine production. (1989) (22)
Conditions for Inducing T Helper Cells In Vitro (1975) (22)
Post-transcriptional control of IL-1 gene expression in the acute monocytic leukemia line THP-1. (1988) (22)
Effect of blocking TNF on IL-6 levels and metastasis in a B16-BL6 melanoma/mouse model. (1997) (22)
Macrophage-lymphocyte interactions in immune induction. (1979) (22)
'Fetal-type' B and T lymphocytes in rheumatoid arthritis and primary Sjögren's syndrome. (1989) (22)
Heterogeneity of accessory cells interacting with T-helper clones. (1986) (21)
TLR Signalling and Adapter Utilization in Primary Human In vitro Differentiated Adipocytes (2012) (21)
Expression of an efficient small molecular weight tumour necrosis factor/lymphotoxin antagonist. (1996) (21)
RelB/p50 regulates CCL19 production, but fails to promote human DC maturation (2009) (21)
Selective enhancement of endothelial cell VCAM‐1 expression by interleukin‐10 in the presence of activated leucocytes (1997) (21)
Increased expression of HLA-DQ antigens by interstitial cells and endothelium in the synovial membrane of rheumatoid arthritis patients compared with reactive arthritis patients. (1989) (21)
An influenza virus matrix protein‐specific human T cell line with helper activity for in vitro anti‐hemagglutinin antibody production (1982) (21)
LPS-induced 111In-eosinophil accumulation in guinea-pig skin: evidence for a role for TNF-alpha. (1995) (21)
The role of macrophages in the generation of T helper cells. V. Evidence for differential activation of short-lived T1 and long-lived T2 lymphocytes by the macrophage factors GRF and NMF. (1977) (21)
In vitro studies on H-2 linked unresponsiveness. 1. Normal helper cells to (T,G)-A-L and GAT in low and non-responder mice. (1977) (20)
Phase I study of TNFα AutoVaccIne in Patients with metastatic cancer (2005) (20)
Pathogenesis of Rheumatoid Arthritis: Cellular and Cytokine Interactions (1992) (20)
HLA-D subregion expression by thyroid epithelium in autoimmune thyroid diseases and induced in vitro. (1987) (19)
Cells with dendritic morphology and bright interleukin‐lα staining circulate in the blood of patients with rheumatoid arthritis (1990) (19)
Identification of TNFR2 and IL-33 as therapeutic targets in localized fibrosis (2019) (19)
The role of cytokines in autoimmunity. (1989) (19)
High-efficiency gene transfer into nontransformed cells: utility for studying gene regulation and analysis of potential therapeutic targets (2002) (19)
The dissociation of interleukin-2 production and antigen-specific helper activity by clonal analysis. (1983) (19)
HU-444, a Novel, Potent Anti-Inflammatory, Nonpsychotropic Cannabinoid (2015) (19)
TNF receptor fusion proteins are effective inhibitors of TNF-mediated cytotoxicity on human KYM-1D4 rhabdomyosarcoma cells. (1994) (18)
Induction of human antigen-specific and non-specific helper factors in vitro. (1979) (18)
Cellular census of human fibrosis defines functionally distinct stromal cell types and states (2020) (18)
Future prospects for anti-cytokine treatment (2000) (18)
Selective inhibition of TNFR1 reduces osteoclast numbers and is differentiated from anti-TNF in a LPS-driven model of inflammatory bone loss. (2015) (18)
Suppression of tumour necrosis factor production from mononuclear cells by a novel synthetic compound, CLX-090717. (2008) (18)
Interleukin 1 (IL-1) and tumour necrosis factor synergise in the induction of IL-1 synthesis by human vascular endothelial cells. (1988) (18)
Epithelial MHC class II sub-region expression in autoimmunity. (1986) (17)
Longitudinal immune profiling reveals distinct features of COVID-19 pathogenesis (2020) (17)
T cells involved in human autoimmune disease are resistant to tolerance induction. (1993) (17)
Mechanism of antigenic competition. II. Induction by specific T cell products. (1974) (17)
Collagen VI as a driver and disease biomarker in human fibrosis (2021) (17)
Immunological effects of IgT synthesized by thetapositive cell lines (1975) (16)
Cytokine therapy in rheumatoid arthritis (1996) (16)
Reversible blocking effect of anti-mouse immunoglobulin serum on the induction of immunity and tolerance in vitro. (1971) (16)
Suppressor cell induction in vitro. VI. Production of suppressor factors to synthetic polypeptides GAT and (T,G)-A--L from cells of responder and nonresponder mice. (1979) (16)
Regulation of the angiopoietin-Tie ligand-receptor system with a novel splice variant of Tie1 reduces the severity of murine arthritis. (2010) (16)
Cellular Basis of Antibody Production (1972) (16)
Prospects for the development of small molecular weight compounds to replace anti-tumour necrosis factor biological agents (2003) (16)
Upregulation of HLA class II, but not intercellular adhesion molecule 1 (ICAM-1) by granulocyte-macrophage colony stimulating factor (GM-CSF) or interleukin-3 (IL-3) in synergy with dexamethasone. (1992) (16)
Study protocol: A multi-centre, double blind, randomised, placebo-controlled, parallel group, phase II trial (RIDD) to determine the efficacy of intra-nodular injection of anti-TNF to control disease progression in early Dupuytren's disease, with an embedded dose response study. (2017) (15)
Cell to cell interactions in the immune response. (1974) (15)
Antigen‐Specific T‐Cell Downregulation by Human Dendritic Cells Following Blockade of NF‐κB (2003) (15)
Glatiramer Acetate Enhances Myeloid-Derived Suppressor Cell Function via Recognition of Paired Ig-like Receptor B (2018) (15)
Characterization of ligand binding by the human p55 tumour-necrosis-factor receptor. Involvement of individual cysteine-rich repeats. (1994) (15)
The method of deriving human T‐cell clones alters the proportion of IL‐10‐producing cells (1996) (14)
Nature of macrophage‐T cell interaction in secondary helper cell generation in vitro Genetic restriction of macrophage‐T cell interaction, which determines T‐B genetic restriction (1981) (14)
Gene expression profiling and functional analysis of angiogenic markers in murine collagen-induced arthritis (2012) (14)
The effects of tumor necrosis factor (TNF) derivatives on TNF receptors. (1993) (14)
The detection by immunofluorescence of distinct cell populations producing interleukin-1α and interleukin-1β in activated human peripheral blood (1989) (14)
T-cell-targeted immunotherapy. (1992) (14)
Relative affinity and avidity of the antigen-binding receptors of T and B rosette-forming cells. (1973) (14)
Immunological time-course of gadolinium-enhancing MRI lesions in patients with multiple sclerosis (1998) (13)
Crystal‐ball gazing − the future of immunological research viewed from the cutting edge (2006) (13)
Immunological intervention reveals reciprocal roles for tumor necrosis factor-α and interleukin-10 in rheumatoid arthritis and systemic lupus erythematosus (2004) (13)
Tumour necrosis factor synergises with gamma interferon on the induction of mRNA for DR alpha chain on thyrocytes from Graves' disease and non toxic goitre. (1989) (13)
Combination therapy with DMARDs and biological agents in collagen-induced arthritis. (1999) (13)
C-type lectin receptor CLEC4A2 promotes tissue adaptation of macrophages and protects against atherosclerosis (2022) (12)
Tumor necrosis factor alpha-induced eosinophil accumulation in rat skin is dependent on alpha4 integrin/vascular cell adhesion molecule-1 adhesion pathways. (1997) (12)
Analysis of cytokine expression in rheumatoid synovium has provided new insights into the pathogenesis of rheumatoid arthritis and new therapeutic opportunities. (2001) (12)
Is genetically related macrophage factor (GRF) a soluble immune response (Ir) gene product? (1979) (12)
A phenotypically dominant regulatory mechanism suppresses major histocompatibility complex class II gene expression in a murine plasmacytoma (1987) (12)
Human epidermal growth factor receptor bispecific ligand trap RB200: abrogation of collagen-induced arthritis in combination with tumour necrosis factor blockade (2011) (12)
Selective production of human antigen specific helper factor from normal volunteers: implications for human Ir genes. (1979) (12)
Nature of T cell-macrophage interaction in helper cell induction in vitro. III. Responsiveness of T cells differentiating in irradiation or allophenic chimeras depends on the genotype of the host. (1980) (11)
Intrathyroidal cytokine production in thyroid disease. (1989) (11)
A monoclonal antibody against antigen-specific helper factor augments T-cell help (1983) (11)
Novel biomarkers of a peripheral blood interferon signature associated with drug-naïve early arthritis patients distinguish persistent from self-limiting disease course (2020) (11)
Antagonism of the human epidermal growth factor receptor family controls disease severity in murine collagen-induced arthritis. (2008) (11)
Mechanism of immune complex-mediated damage: induction of interleukin 1 by immune complexes and synergy with interferon-gamma and tumor necrosis factor-alpha. (1989) (11)
Rheumatoid arthritis: pathogenic mechanisms and therapeutic targets (2004) (11)
Cannabinoids in Models of Chronic Inflammatory Conditions (2004) (11)
Endotoxin signaling in human macrophages: signaling via an alternate mechanism (2004) (10)
T-cell hybridomas producing hapten-specific suppressor factors. (1981) (10)
ANTIGEN SPECIFIC T CELL FACTORS AND THEIR ROLE IN THE REGULATION OF T-B INTERACTION (1974) (10)
Antigen-specific helper factor reacts with antibodies to human beta 2 microglobulin. (1981) (10)
Heterogeneity of accessory cells. (1984) (10)
A shift in lung macrophage composition is associated with COVID-19 severity and recovery (2022) (10)
Humoral and cellular responses raised against the human HER2 oncoprotein are cross-reactive with the homologous product of the neu proto-oncogene, but do not protect rats against B104 tumors expressing mutated neu (1996) (10)
Role of epitope density in the induction of tolerance and immunity with thymus‐independent antigens. III. Interaction of epitope density and receptor avidity (1976) (10)
Mechanism of Graves thyroiditis: implications for concepts and therapy of autoimmunity. (1992) (10)
Reduced synovial vascularity following TNF alpha blockade in rheumatoid arthritis. (1998) (10)
The relationship between secreted and cell surface antigen-binding molecules synthesized by T cells. I. Function-related isotypic determinants on T cells defined by antisera to antigen-specific helper and suppressor factors. (1984) (10)
Are the Ir genes expressed by macrophages? (1977) (10)
The detection of autoantibody-forming cells. II. Cells in lymph nodes and central nervous system containing antibody to myelin basic protein. (1972) (9)
The pitfalls in the development of biologic therapy (2007) (9)
Study protocol: A multi-centre, double blind, randomised, placebo-controlled, parallel group, phase II trial (RIDD) to determine the efficacy of intra-nodular injection of anti-TNF to control disease progression in early Dupuytren’s disease, with an embedded dose response study. (2017) (9)
Selective immunosuppression of tumour necrosis factor-alpha in rheumatoid arthritis. (1995) (9)
Induction of human antigen-specific suppressor factors in vitro. (1981) (9)
The effect of erythrocyte antigen structure on requirement for T cells. (1974) (9)
THE TOLL-LIKE RECEPTOR-NUCLEAR FACTOR κ B PATHWAY IN RHEUMATOID ARTHRITIS (2005) (9)
Phase I study of TNFalpha AutoVaccIne in patients with metastatic cancer. (2005) (9)
RelB / p 50 regulates TNF production in LPS-stimulated dendritic cells and macrophages (2013) (9)
Regulation of Immune Gene Expression (1986) (8)
Targeting intracellular mediators of pattern-recognition receptor signalling to adjuvant vaccination. (2007) (8)
Effect of soluble P55 tumour‐necrosis factor binding fusion protein on the local Shwartzman and Arthus reactions (1996) (8)
Regulation of clonal growth by anti-T-cell receptor antibody-directed lysis. (1988) (8)
Do CD4-positive cytotoxic T cells damage islet beta cells in type 1 diabetes? (1988) (8)
Antigen Presentation by Dendritic Cells (1984) (8)
Shift of lung macrophage composition is associated with COVID-19 disease severity and recovery (2022) (8)
High Rate of HLA Class II mRNA Synthesis in Rheumatoid Arthritis Joints and Its Persistence in Culture: Down‐Regulation by Recombinant Interleukin 2 (1989) (8)
IL-4-Induced Eosinophil Accumulation in Rat Skin Is Dependent on Endogenous TNF-α and α4 Integrin/VCAM-1 Adhesion Pathways (1998) (8)
Does TNFα Have a Pivotal Role in the Cytokine Network in Rheumatoid Arthritis (1993) (7)
Regulation of macrophage accessory cell activity by mycobacteria. I. Ia expression in normal and irradiated mice infected with Mycobacterium microti. (1986) (7)
Direct evaluation of antigen binding to human T lymphocyte clones: involvement of major histocompatibility complex products in antigen binding (1984) (7)
Regulation of HLA class II expression and the pathogenesis of autoimmunity. (1988) (7)
Interleukin 7 and interleukin 4 stimulate human thymocyte growth through distinct mechanisms. (1990) (7)
INDUCTION IN VITRO OF IMMUNOLOGICAL TOLERANCE TO THE H‐ANTIGENS OF SALMONELLA ADELAIDE * (1971) (7)
The role of soluble factors in T-B cell collaboration. (1973) (7)
New approaches to therapeutic immunomodulation for immune-mediated inflammatory disorders. (2004) (7)
Unraveling the interactions between postoperative infection, surgery, and inflammation in post-operative cognitive dysfunction: BAPCPC1–4 (2010) (7)
T-cell activation in health and disease. (1988) (7)
Human T Cell Clones: A New Approach to Immune Regulation (1985) (7)
IN VITRO RESPONSES UNDER I REGION CONTROL (1978) (7)
High efficiency gene transfer is an efficient way of defining therapeutic targets: a functional genomics approach (2001) (7)
Role of HLA class II and cytokine expression in rheumatoid arthritis. (1988) (7)
Role of Macrophages in the in Vitro Induction and Regulation of Antibody Responses (1980) (7)
Monoclonal T cells and their products (1982) (6)
T-cell clone anti-clone interactions. Effects on suppressor and helper activities. (1989) (6)
Comparative and combined effects of transforming growth factors alpha and beta, interleukin-1 and interferon-gamma on rheumatoid synovial cell proliferation, glycolysis and prostaglandin E production. (1989) (6)
2 – Aetiopathogenesis of Rheumatoid Arthritis (1995) (6)
Transforming Growth Factor Beta Regulates Thyroid Growth (6)
The detection of autoantibody-forming cells. I. An assay for plaque-forming cells to the basic protein of myelin in guinea-pigs. (1972) (6)
Requirement for interactions between two subpopulations of T cells for helper cell induction in vitro. (1977) (6)
Collagen-induced arthritis as a model of hyperalgesia (2007) (6)
The murine p75 TNF receptor promoter region: DNA sequence and characterization of a cis-acting silencer. (1999) (6)
T cell hybrids with T cell functions. (1978) (6)
Evidence for a DC‐Specific Inhibitory Mechanism that Depends on MyD88 and SIGIRR (2010) (6)
Dissecting the Role of BET Bromodomain Proteins BRD2 and BRD4 in Human NK Cell Function (2021) (6)
New ideas in thyroid autoimmunity. (1987) (6)
COMPARISON OF ANTIGEN‐SPECIFIC I‐REGION‐ASSOCIATED CELL INTERACTION FACTORS (1979) (6)
Interactions between autologous T cell clones. (1990) (6)
Use of anti-tumor necrosis factor antibodies in rheumatoid arthritis. (1994) (6)
Genetics of human T cell-monocyte interaction in helper cell induction. (1981) (6)
Specific Interactions between a Human CD4+ Clone and Autologous CD4+ Bifunctional Immunoregulatory Clones (1990) (5)
C‐erbB‐2 oncoprotein in screen‐detected breast carcinoma: An immunohistological study (1993) (5)
Cytokine networks: do we understand them well enough to facilitate clinical benefits? (1991) (5)
Novel CBG Derivatives Can Reduce Inflammation, Pain and Obesity (2021) (5)
Thymus-independent IgM and IgG responses in mice to flagellar antigens. (1974) (5)
Single cell force profiling of human myofibroblasts reveals a biophysical spectrum of cell states. (2020) (5)
Resting CD 4 + effector memory T cells are precursors of bystander-activated effectors : a surrogate model of rheumatoid arthritis synovial T-cell function (2015) (5)
Induction of low-zone tolerance in vitro. (1971) (5)
A vasculature niche orchestrates stromal cell phenotype through PDGF signaling: Importance in human fibrotic disease (2022) (5)
Rheumatoid arthritis: introduction (2004) (5)
TF ligation by factor VIIa induces pro-inflammatory cytokine production in atheroma smooth muscle cells (2006) (5)
The Heterogeneity of Autoimmune Responses (1985) (5)
Flavone acetic acid (FAA) with recombinant interleukin-2 (rIL-2) in advanced malignant melanoma. III: Cytokine studies. (1993) (5)
Definition of function-related isotypic markers on T cells. (1982) (5)
Design and Optimisation of Bioactive Cyclic Peptides: Generation of a Down-Regulator of TNF Secretion (2014) (5)
The effect of tumour necrosis factor-α (TNF-α) muteins on human neutrophils in vitro (1993) (5)
Analysis of T cell clones in rheumatoid arthritis (2005) (5)
Antigen-Specific Regulatory Factors in the Immune Response (1979) (5)
Comparative and combined effects of transforming growth factors α and β, interleukin-1 and interferon-γ on rheumatoid synovial cell proliferation, glycolysis and prostaglandin E production (2004) (5)
Insights into the pathogenesis of rheumatoid arthritis from application of anti-TNF therapy. (2000) (4)
Induction of antibody responses in vivo by antigen specific helper factor. (1979) (4)
Regulatory Interactions among Autologous T Cell Clones Human Bifunctional T Cell Clones Regulate the Activity of an Autologous T Cell Clone a (1991) (4)
Human alpha beta T-cell receptor CD4-CD8 T-cell clones are predominantly Th0-like. (1995) (4)
AUTOANTIGEN PRESENTATION BY TARGET-CELLS - ITS POSSIBLE ROLE IN DETERMINING AUTOANTIBODY SPECIFICITY (1986) (4)
Inappropriate HLA class II expression on epithelial cells: new insight in the pathogenesis of distinctive autoimmunity. (1986) (4)
Anti-tumour necrosis factor therapy for early-stage Dupuytren’s disease (RIDD): a phase 2b, randomised, double-blind, placebo-controlled trial (2022) (4)
TNF as a therapeutic target (2000) (4)
Adenoviral Gene Transfer of the Endogenous Inhibitor IκBα into Human Osteoarthritis Synovial Fibroblasts Demonstrates That Several Matrix Metalloproteinases and Aggrecanases Are Nuclear Factor-κB-Dependent (2007) (4)
Inhibition of histone H 3 K 27 demethylases selectively modulates inflammatory phenotypes of natural killer cells (2018) (4)
Immunology: Lymphokines and interleukins emerge from the primeval soup (1985) (4)
The immunoregulatory role of interleukin-10 in Crohn's disease (CD)cell cultures (2000) (4)
Single cell force profiling of human myofibroblasts reveals a biophysical spectrum of cell states (2020) (4)
Increased urinary free immunoglobulin light chain excretion in patients with multiple sclerosis (2010) (4)
Complement in the Induction of IgA and IgE Antibody Production (1976) (4)
Specific T helper and suppressor cells and factors induced in vitro to the hapten NP. (1980) (4)
Cytokines as therapeutics and targets of therapeutics (2006) (3)
Antibody production to antigen-specific factors. (1980) (3)
Biochemical events initiated by exposure of human T lymphocyte clones to immunogenic and tolerogenic concentrations of antigen (1985) (3)
CELL INTERACTIONS IN ANTIBODY PRODUCTION - PROBLEMS OF HETEROGENEITY, DIVERSITY AND REGULATION (1975) (3)
Minimal tumor necrosis factor receptor binding protein: optimum biological activity of a truncated p55 soluble tumor necrosis factor receptor-IgG fusion protein. (1998) (3)
Multiple sclerosis: a localised immune disease of the central nervous system (1989) (3)
Role of IL-1 in the Activation and Inactivation of Human T-Cell Clones: Relevance to Rheumatological Disease (1985) (3)
Influence of antigen structure on the activation and induction of unresponsiveness in cloned human T lymphocytes. (1986) (3)
Author Correction: Cellular census of human fibrosis defines functionally distinct stromal cell types and states (2020) (3)
ROLE OF T‐CELL IMMUNOGLOBULIN IN CELL COOPERATION, T‐CELL SUPPRESSION, AND ANTIGENIC COMPETITION (1975) (3)
CD4+ T-CELL DAMAGE TO ISLET BETA CELLS (1989) (3)
Understanding what infiltrating cells do in autoimmunity: combination of cellular and molecular approaches. (1988) (3)
Induction of a T-cell mediated suppressor activity by soluble products from antigen-specific helper/inducer human T-cell lines. (1983) (3)
POI18 Increased urinary free immunoglobulin light chain excretion in patients with multiple sclerosis (2010) (3)
From the laboratory to the clinic: Evaluation of cytokines in rheumatoid arthritis highlights TNF-alpha as a new therapeutic target (1994) (3)
Prospects for cytokines in human immunotherapy (1994) (3)
Directed issue: novel concepts in inflammation. (2010) (3)
ON THE NATURE OF SPECIFIC FACTORS AND THE INTEGRATION OF THEIR SIGNALS BY MACROPHAGES (1979) (3)
A Lymphotoxin-Driven Pathway to Hepatocellular Carcinoma (2011) (3)
Receptor Activation by Antigens, Cytokines, Hormones and Growth Factors (1995) (3)
Lymphoid cell interactions in Japan (1976) (3)
Complementation ofH-2-linkedIr genes: Use of helper factor to analyze responses to GLPhe (1978) (3)
Antigenic phenotypes of T-cell subsets. (1977) (2)
Autoimmune disease: synergy of HLA class II overexpression and abrogation of self tolerance. (1986) (2)
CHAPTER 13 – HUMAN ANTIGEN SPECIFIC HELPER T CELL FACTORS IN B CELL RESPONSES (1979) (2)
Definition of TNFα as a therapeutic target for rheumatoid arthritis (2004) (2)
Macrophage heterogeneity in the context of rheumatic diseases (2016) (2)
CHAPTER 52 – Autoimmunity and cytokines: pathogenesis and therapy (2003) (2)
Genetic Control of Immune Suppression (1978) (2)
HUMAN T‐CELL RESPONSES IN VITRO: CELL INTERACTIONS AND FACTORS (1979) (2)
EFFECT OF ANTIGEN STRUCTURE ON THE INDUCTION OF TOLERANCE IN T CELLS (1974) (2)
B Cell Stimulatory Factor 2 (BSF2/IL-6) and Rheumatoid Arthritis (1987) (2)
The stable infection of epithelial cell lines and primary rabbit colon cells with anadenovirusencoding murine interleukin-10 (mIL-10) generates bioactive cytokine at therapeutic concentrations (2000) (2)
C-type lectin receptor CLEC4A2 promotes tissue adaptation of macrophages and protects against atherosclerosis (2022) (2)
VEGF EXPRESSION IN HUMAN MACROPHAGES IS NF kappa B-DEPENDENT: STUDIES USING ADENOVIRUSES EXPRESSING A KINASE DEFECTIVE FORM OF IKK2 or I kappa B alpha THE NATURAL NF kappa B INHIBITOR (2002) (2)
FRI0020 Blocking the inhibitory CD94/NKG2A NK cell receptor with a novel ANTI-NKG2A MAB enhances the susceptibility of rheumatoid arthritis fibroblast-like synoviocytes (FLS) to NK cell-mediated cytotoxicity (2013) (2)
Pain reduction and lack of psychotropic effects with ajulemic acid: comment on the article by Sumariwalla et al - Reply (2004) (2)
Thyrocytes can synthesize HLA class II molecules. (1987) (2)
Host-targeting oral antiviral drugs to prevent pandemics (2022) (2)
Many cytokines are very useful therapeutic targets (2008) (2)
Responses in Mouse Liver Reduces Adenovirus-Mediated Inflammatory Established Collagen-Induced Arthritis and Murine IL-10 Gene Transfer Inhibits (2001) (2)
A comparative study of accessory cells derived from the peritoneum and from solid tissues. (1982) (2)
Host Pattern Recognition Receptors (Toll-Like Receptors, RIG-I-Like Receptors, NOD-Like Receptors) and Atherosclerosis (2012) (2)
Positronen-Emissions-Tomographie (2012) (2)
Synovial fibroblasts are important mediators of synovial angiogenesis in the hypoxic rheumatoid joint (2006) (2)
Antigen-specific and non-specific helper activities derived from supernatants of human influenza virus-specific T-cell lines. (1983) (2)
Cytokines in autoimmunity. (1992) (2)
Characterization of macrophage derived factors effective in T-helper cell induction (1976) (2)
Autoimmune thyroiditis and targeted anti-T cell immunotherapy in man. (1992) (2)
Can Epithelial Cells Present Surface Autoantigens (1985) (2)
Gene therapy for rheumatoid arthritis? (2001) (2)
Cellular basis of the humoral immune response in mouse and hamster. (1978) (2)
TREATMENT OF RHEUMATOID-ARTHRITIS WITH ANTIBODY TO TNF-ALPHA DECREASES EXPRESSION AND SHEDDING OF E-SELECTIN (1995) (1)
Human and mouse specific T-cell helper factors assayed in vivo and in vitro: implications for human Ir genes. (1979) (1)
Hypoxia and cytokines induce a natural antisense transcript (aHIF) to regulate HIF-1 mediated angiogenesis in rheumatoid arthritis (2012) (1)
New approaches to inhibiting TNF production in rheumatoid arthritis: is pathological TNF regulated in the same way as protective TNF? (2001) (1)
Antigen specific T cell factors (1980) (1)
The specificity of immunological recognition in natural and acquired tolerance. (1965) (1)
The Role of TNFα in the Pathogenesis of Rheumatoid Synovitis (1999) (1)
Identification and Characterization of TMI-1, a Novel Dual TACE/MMP Inhibitor for the Treatment of RA (2003) (1)
Potentiation of TNF-alpha toxicity by conjugation with ricin A-chain. (1998) (1)
Bone Research Society, Annual Meeting 2017 Proceedings (2018) (1)
Anti-TNF (adalimumab) injection for the treatment of adults with frozen shoulder during the pain predominant stage protocol for a multi-centre, randomised, double blind, parallel group, feasibility trial (2022) (1)
Mitogen-Activated Protein Kinases : Role of the p 38 α Endogenous IL-1 and TNF-Regulation of Monocyte IL-10 Synthesis by Feldmann (1998) (1)
GENETIC CONTROL OF T CELL-MACROPHAGE INTERACTION IN HELPER CELL INDUCTION IN VITRO11Supported by the Juvenile Diabetes Foundation, grant No. 78R085, The Imperial Cancer Research Fund and Medical Research Council. (1980) (1)
Cytokines and inflammatory mediators 25. Certolizumab Pegol has a Different Profile from the other Anti-TNFS, Including Golimumab, in a Variety of in Vitro Assays (2011) (1)
SELECTIVE USAGE OF IKK2 FOR NF-kappa B ACTIVATION AND PRO-INFLAMMATORY GENE EXPRESSION: STUDIES IN HUMAN PRIMARY CELLS AND RHEUMATOID SYNOVIAL MEMBRANE CELL CULTURES (2002) (1)
Mechanism of action of immune response genes. (1984) (1)
INFLUENCE OF ANTIGENIC MATRICES ON THE ANTIBODY RESPONSE (1975) (1)
Complexity of cell interactions: analysis using antigens under Ir gene control. (1978) (1)
Human Autoreactive T‐Cell Clones Show Flexibility in Recognizing Overlapping Microepitopes, but Inflexibility in T‐Cell Receptor Usage a (1995) (1)
Targeting intracellular signaling: a novel approach to vaccination (2007) (1)
Selective activation of blood T cells in children with newly diagnosed insulin dependent diabetes mellitus. (1994) (1)
Immunotherapy: Editorial overview (2001) (1)
The detection by immunofluorescence of distinct cell populations producing interleukin-1 alpha and interleukin-1 beta in activated human peripheral blood. (1989) (1)
Book Review: Cellular Immunology (1982) (1)
BIOCHEMICAL AND CELLULAR QUESTIONS IN ANTIGEN PROCESSING (1986) (1)
Specific suppression of antibody responses in vivo. I. Effects of in vitro produced suppressor factor. (1982) (1)
Analysis of Intrathyroidal Cytokine Production in Thyroid Disease (1991) (1)
AUTOREACTIVITY AGAINST CLASS-I OR CLASS-II ANTIGENS - IMMUNOLOGICAL DOWN-REGULATION MECHANISM (1989) (1)
Comparison of peptide and superantigen-induced anergy in a peptide-specific polyclonal human T cell line. (1995) (1)
Anti-TNF Therapy: 20 Years from Our First Therapeutic Adventure (2014) (1)
CD5+B cells in rheumatoid arthritis and Sjögren's syndrome. (1990) (1)
[A change in the expression of histocompatibility antigens could lead to autoimmunity]. (1984) (1)
Antilipid A monoclonal antibody HA-1A decreases the capacity of bacterial lipopolysaccharide to activate human vascular endothelial cells by an immune adherence mechanism. (1993) (1)
Antigen presentation by dendritic cells is NF kappa B dependent in vitro and in vivo [abstract] (2001) (1)
Interleukin-1 and tumour necrosis factor mRNA expression in rheumatoid arthritis: prolonged production of IL-la (2006) (1)
Targeting TNFα for the therapy of rheumatoid arthritis (1994) (1)
Adaptor for LPS and LTA Signaling in Primary Human Cells : TRAM Is an B Activation and Cytokine Production κ NF-( LPS ) and Lipoteichoic Acid ( LTA ) Induced Selective Use of TRAM in Lipopolysaccharide (2007) (0)
Focused ultrasound for treatment of peripheral brain tumors (2023) (0)
Cytokines in Cancer Therapy : By Frances Balkwill; Oxford University Press; Oxford, 1989; xvi + 297 pages; £30.00 (hardback), £18.50 (paperback) (1990) (0)
Present state and future of biologics in autoimmune diseases 1: Cytokines (CS-2) Chairpersons: Josef Smolen, Yoshiya Tanaka (2010) (0)
LOCAL GENE THERAPY OF EAE WITH CTLA4-IMMUNOGLOBULIN FUSION PROTEIN (1998) (0)
The TNF/TNF-R family: A gold mine for clinical therapeutic targets? (2011) (0)
Preface (2002) (0)
Abstract 5674: Toll-like Receptor-2 and -4 Signaling Regulates Inflammation and Matrix Degradation in the Human Atherosclerotic Plaque (2009) (0)
11 THE EXPRESSION OF TLR3 IS INCREASED IN ATHEROSCLEROSIS AND MEDIATES PROTECTION AGAINST LESION DEVELOPMENT AND WEIGHT GAIN IN APOE−/− MICE (2011) (0)
Chemokine production from endothelial cells is induced by activated T cells in a contact-dependent manner: a role for cell-cell contact interactions in the pathogenesis of atherosclerosis (2000) (0)
Author Correction: Cellular census of human fibrosis defines functionally distinct stromal cell types and states (2020) (0)
REGULATION OF VASCULAR ENDOTHELIAL GROWTH FACTOR (VEGF) IN RHEUMATOID ARTHRITIS BY THE TRANSCRIPTION FACTOR NF kappa B (2003) (0)
MODULATION OF CYTOKINE PRODUCTION AND FUNCTION BY TRANSFORMING GROWTH-FACTOR-BETA (1990) (0)
Advanced glycation end products (AGEs) augment production of vascular endothelial growth factor (VEGF) and tumor necrosis factor alpha (TNF alpha) in human monocyte-derived macrophages. (2003) (0)
CELL INTERACTIONS I N T H E I M M U N E RESPONSE I N VITRO I I I . SPECIFIC COLLABORATION ACROSS A CELL IMPERMEABLE MEMBRANE* BY MARC FELDMANN$ AND ANTONY BASTEN§ (2003) (0)
Selective modulation of Natural Killer (NK) cell phenotypes through chromatin modifying mechanisms (2016) (0)
Tumour Necrosis Factor: A Prometastatic Role in Breast Cancer (2003) (0)
Human T cell clones, tolerance, and the analysis of autoimmunity. (1986) (0)
Long-term beneficial responses to therapy with a monoclonal antibody to TNF-alpha in patients with rheumatoid arthritis (1994) (0)
Towards the development of a universal T cell influenza (FLU) vaccine (52.10) (2010) (0)
Cellular interactions in antibody production (1978) (0)
Genetic Restriction of T-Macrophage Interactions: Is It Induced by Priming or Present Prior to Priming? (1978) (0)
Role of the Reticuloendothelial System in T-Helper Cell Induction (1984) (0)
Induction of autoimmunity: is there a role for infectious agents? (1987) (0)
Lymphocytes, Macrophages, and Cancer, G. Mathé, I. Florentin, M.-C. Simmler (Eds.). Springer-Verlag, Berlin • Heidelberg • New York (1976), 53 figs., IX, 160 pages, US-$ 23.00 (1979) (0)
Colony-Stimulating Factors. Molecular and Cellular Biology (1990) (0)
The lymphokines: Biochemistry and biological activity Edited by J. W. Hadden and W. E. Stuart II. Clifton, New Jersey: Humana Press (1981). 464 pp. $59.50 (1982) (0)
Novel Synthesis of C-Methylated Phytocannabinoids Bearing Anti-inflammatory Properties (2023) (0)
Analysis of endocrine autoimmunity by cloning human T lymphocytes from target tissues (1987) (0)
HLA-D Region Expression on Thyrocytes: Role in Stimulating Autoreactive T Cell Clones (1986) (0)
Dimeric TNF Receptor Using Cells Expressing a Novel Soluble p75 Experimental Allergic Encephalomyelitis Gene Therapy for Chronic Relapsing (2000) (0)
Increased Urinary Neopterin Excretion in Vaccinated Adults (1996) (0)
7.4 Suppression of HLA class II in thyroid epithelial cells (1989) (0)
The co-localisation of tumour necrosis factor a (Tnf) and its receptor in rheumatoid arthritis (ra) synovial membrane. (1991) (0)
Cloning of Autoimmune T Cells: Implications for Pathogenesis and Therapy (1985) (0)
Procedes permettant d'induire une reaction immunitaire avec un rapport th1 :th2 eleve par induction intracellulaire de nfkappab (2002) (0)
Inhibition of tissue factor by blockade of NFkB and IKK-2 using gene transfer: NFkB as a therapeutic target for reducing plaque thrombogenicity (2002) (0)
Hon-1 Anti TNF and the beginning of anti cytokine medicine (2008) (0)
Identification and Characterization of 4-[ [ 4-( 2-Butynyloxy ) phenyl ] sulfonyl ]-N-hydroxy-2 , 2-dimethyl-( 3 S )-thiomorpholinecarboxamide ( TMI-1 ) , a Novel Dual Tumor Necrosis Factor-- Converting Enzyme / Matrix Metalloprotease Inhibitor for the Treatment of Rheumatoid Arthritis (2004) (0)
PNAS Plus Significance Statements (2012) (0)
Immunomodulation of Cytokines and T Cells by Biologicals in Rheumatoid Arthritis (2020) (0)
NF-kappa B dependent pathways of matrix metalloproteinase induction in rheumatoid arthritis (1999) (0)
Antigen Specific Helper Factors: An Overview after Ten Years (1983) (0)
Selective production ofhumanantigen specific helper factor fromnormal volunteers: implications forhumanIrgenes (1979) (0)
Structure of antigen-specific suppressor factors: Current views (1982) (0)
c-erbB-2 expression indifferent histological types ofinvasive breast carcinoma (1991) (0)
CD4 T cells can lyse islet β cells in type 1 diabetes (1990) (0)
EffectiveTargeting of theTumor Microenvironment for CancerTherapy (2012) (0)
Collagen-Induced Arthritis Blockade of TNF Activity in Murine Paradoxical Effects of Adenovirus-Mediated Buurman (1999) (0)
Membrane Cultures from Human Rheumatoid Synovial Inhibitors of TLR8 Reduce TNF Production (2008) (0)
Clonal approaches to immune regulation by lymphocytes. (1984) (0)
CYTOKINES IN RHEUMATOID ARTHRITIS : IS TNFα OF HAAJOR IMPORTANCE? (1993) (0)
Referees (1991) (0)
Exocrine Proteins Including Trypsin(ogen) as a Key Biomarker in Type 1 Diabetes. (2023) (0)
Anti-TNF antibody / tnf receptor and methotrexate for treatment of autoimmune diseases (1997) (0)
Cd4 negative cd8 negative t cells expressing the alpha beta t cell receptor responsive to il 2 il 3 and il 4 (1989) (0)
Activated T-cells stimulate endothelial cells to release proinflammatory cytokines in a contact-dependent manner: A clue about the pathogenesis of atherosclerosis? (2000) (0)
Effects of monoclonal antibodies raised against antigen-specific factors☆☆☆ (1982) (0)
Novel biomarkers of a peripheral blood interferon signature associated with drug-naïve early arthritis patients distinguish persistent from self-limiting disease course (2020) (0)
ON THE NATURE OF ANTIGEN-SPECIFIC T CELL FACTORS (1980) (0)
Use of cannabinoids as anti-inflamatoprios agents. (1999) (0)
Genetically restricted and unrestricted antigen specific helper factors (1982) (0)
IN VITRO studies on the cellular basis of the unresponsiveness in mice to (TG)AL (1976) (0)
THE NFKB PATHWAY IS INVOLVED IN VEGF-INDUCED SURVIVAL IN HUMAN ENDOTHELIAL CELLS (2004) (0)
HMGB1 accelerates regeneration of multiple tissues by transitioning stem cells to G(Alert) (2017) (0)
Treatment of autoimmune and entzundungskrankheiten (1993) (0)
Augmentation of cell-mediated responses in vitro by a monoclonal anti-helper factor antibody. (1985) (0)
Definition of the tri-molecular complex of human thyroid peroxidase specific autoreactive t-cell clones (1993) (0)
Modulation of hla class ii expression of the thyroid in relation to autoimmune stimulation by target cells (1988) (0)
Natural killer (NK) cells and gamma delta T-cells differentially modulate Th17-driven disease in ankylosing spondylitis (2014) (0)
Abstract 4446: Molecular profiling and threshold expression of microRNAs in mammary tissue of asymptomatic women (2017) (0)
Arthritis Implications for Therapy in Rheumatoid B with κ p 38 MAPK : Involvement of NF-Regulation by α A Novel Mechanism for TNF - (2004) (0)
VEGF expression in human macrophages is NFkB-dependent: studies using adenoviral gene transfer (2000) (0)
Adenoviral gene transfer into osteoarthritis synovial cells using the endogenous inhibitor I j B a reveals that most, but not all, inﬂammatory and destructive mediators are NF j B dependent (2006) (0)
Direct analysis of gene expression and regulation in human atherosclerotic tissue: Nuclear factor kappa B regulates production of cytokines and tissue factor (2002) (0)
A process for the treatment of vascular diseases by tumor necrosis factor antagonists (1997) (0)
ACCESSORY CELL HETEROGENEITY IN ANTI-MYCOBACTERIAL RESPONSES (1984) (0)
NK cells support osteoclast formation in vitro (2004) (0)
Special Lectures on the Pathogenesis and the Pathogenesis-based Treatment of Rheumatoid Arthritis. Insights into the pathogenesis of rheumatoid arthritis from application of anti-TNF therapy. (2000) (0)
EFFECTS OF EPIDERMAL GROWTH-FACTOR (EGF) AND PLATELET DERIVED GROWTH-FACTOR (PDGF) ON ANTIGEN DRIVEN LYMPHOCYTE-T PROLIFERATION INVITRO (1984) (0)
EFFECT OF EPITOPE DENSITY ON THE INDUCTION OF TOLERANCE IN VITRO (1974) (0)
[Cellular mechanisms of regulation of the inflammatory response in atherosclerosis: the role of cell contact-mediated signaling]. (2001) (0)
Autoimmune disorders-analysis by study of T cells, implications and speculations (1986) (0)
V. SPECIFIC COLLABORATION VIA COMPLEXES OF ANTIGEN AND THYMUS-DERIVED CELL IMMUNOGLOBULIN* BY MARC FELDMANN$ (2003) (0)
REDUCTION OF TNFalpha AND IL-12 IN THERAPY (1997) (0)
Administration of protease-activated kringles 1–5 (K1–5) reduces joint destruction in collagen-i (2011) (0)
Antibody therapy (SY5-2) Chairpersons: Norihiro Nishimoto, Jeffrey V. Ravetch (2010) (0)
Activation of NF- (cid:1) B by the intracellular expression of NF- (cid:1) B-inducing kinase acts as a powerful vaccine adjuvant (2006) (0)
Interleukin-1 Receptor Antagonist Isoforms in Collagen-Induced Arthritis (1999) (0)
Proceedings of the 12th International TNF Conference, 2009. (2011) (0)
A protective role for toll-like receptor 3 but not toll-like receptor 7 in intimal hyperplasia (2011) (0)
Development of Humanized Bispecitic Antibodies Reactive with Cytotoxic Lymphocytes and Tumor (2003) (0)
Comprar Advances In Tnf Family Research. Proceedings Of The 12th International Tnf Conference, 2009 (Advances In Experimental Medicine And Biology, Vol. 691) | Andrew Kovalenko | 9781441966117 | Springer (2010) (0)
Skin Is Dependent on Endogenous TNF- IL-4-Induced Eosinophil Accumulation in Rat (1998) (0)
Primate Helper Factors: Comment on the ‘Antigen Bridge’ (1983) (0)
Selected Aspects of the Immunopharmacology of Cytokines (1995) (0)
Discovery and Development of Anti-TNF Therapy (2015) (0)
REQUIREMENT FOR NF kappa B AND IKK-2 IN TISSUE FACTOR EXPRESSION BY CELLS RELEVANT TO THE PATHOGENESIS OF ATHEROSCLEROSIS AND RHEUMATOID ARTHRITIS (2002) (0)
The effect of cyclosporin A on IL-2 receptor expression and IL-2 production both in vivo and in vitro (1987) (0)
CD5 + B Cells and Double-Negative T Cells in Rheumatoid Arthritis (1992) (0)
[Recombinant adenovirus-mediated gene transfer suppresses experimental arthritis] (2011) (0)
Cellular census of human fibrosis defines functionally distinct stromal cell types and states (2020) (0)
STIMULATION OF HUMAN AND MURINE THYMOCYTE PROLIFERATION BY INTERLEUKIN-7 (1990) (0)
Themajority oftheactivated T cells inthebloodof insulin-dependent diabetes mellitus (IDDM)patients areCD4+ (1988) (0)
Monoclonal Antibodies Against Ia +, Antigen Specific T Cell Factors (1983) (0)
A N T I B O D Y-M E D I A T E D SUPPRESSION OF T H E I M M U N E RESPONSE I N VITRO (2003) (0)
Epigenetic modulation of NK cell phenotypes 1 Inhibition of histone H3K27 demethylase selectively modulates inflammatory phenotypes of natural killer cells (2018) (0)
Th1/Th2 response in CIA: Dominant role of IFN gamma and IL-12 in the induction of arthritis (1996) (0)
THE REQUIREMENT FOR MACROPHAGES IN CYTOTOXIC REACTIONS AGAINST CELL-BOuND AND SUBCELLULAR ALLOANTIGENS BY HERMANN WAGNER,$ (2003) (0)
General Discussion II (1981) (0)
Factor-Cytokines Are Inhibited , But IL-10 Is Nuclear Zymosan-Induced , Proinflammatory Lipopolysaccharide-Induced , But Not Human Macrophages : into α B κ Adenoviral Gene Transfer of I Selective Regulation of Cytokine Induction by (1999) (0)
Mechanism of antigen binding to receptor antibody in B cell immunity and tolerance in vitro. (1973) (0)
RES-Leukocyte Interactions (1984) (0)
Inflammation and underlying postoperative cognitive decline (2012) (0)
Deletion TNFalpha and IL-12 in therapy. (1997) (0)
Comparison of the cellular infiltrate of Hashimoto's thyroiditis in vivo and after in vitro cell growth. (1987) (0)
Th2 cytokine-producing cells Critical role of CD28/B7 costimulation in the development of human (2011) (0)
CELLS THAT SUPPRESS IMMUNITY (1986) (0)
Gene therapy of experimental allergic encephalomyelitis (EAE) with dimeric TNF receptors using cells as biological pumps (1998) (0)
T Lymphocytes Today (1984) (0)
Arthritis Therapy in Rheumatoid α Anti-TNF-and Acute-Phase Proteins Following Regulation of Cytokines , Cytokine Inhibitors , (1999) (0)
Reply: To PMID 23784528. (2014) (0)
Treatment of collagen-induced arthritis with cholera toxin-treated dendritic cells (2005) (0)
utilization of MyD88 and Mal/TIRAP selective production in human myeloid and non-myeloid cells defined by B activation and cytokine κ Distinct pathways of LPS-induced NF- (2013) (0)
Adenoviral gene therapy of experimental allergic encephalomyelitis (EAE) with CTLA4-Ig (1998) (0)
The interleukins (contemporary topics in molecular immunology, vol. 10): edited by Steven Gillis and F. P. Inman, Plenum, 1985. $42.50 (xxi + 291 pages) ISBN 0 306 41776 6 (1985) (0)
Reply (2014) (0)
Definition of a population of CD 4-8-T cells that express the ( 43 T-cell receptor and respond to interleukins 2 , 3 , and 4 ( lymphocytes / lymphokines / thymus / ontogeny ) (0)
Use of TNF antagonists to reduce the Plasmafribinogenspiegels (1997) (0)
Inhibition of VEGF in human macrophages and rheumatoid synovial cells by blockade of the NF kappa B pathway using adenoviral gene transfer (2002) (0)
P058 Persistence of neutrophil abnormalities in COVID-19 convalescence (2021) (0)
Effective cognitive assessment in the management of post-operative delirium (2009) (0)
ACTIVATION OF THE IMMUNE SYSTEM BY AN ANTIGEN AND A NF-kappaB-TIMER (2000) (0)
A method for the treatment of multiple sclerosis (1993) (0)
Cell Interactions in T H E I M M U N E Response in Vitro Ii. the Require]y[ent for Macrophages in Lym~hom Cell Collaboration S (0)
Human T-cell receptor CD4-CD8 T-cell clones arepredominantly ThO-like (1994) (0)
78 TREM-1 expression is increased in the Synovium of Rheumatoid Arthritis patients and induces the expression of pro-inflammatory cytokines (2008) (0)
Antigen Recognition by Human Influenza Virus Specific Helper T Lymphocyte Clones (1985) (0)
MLC and CMC reactivity and specificity of idiotype-specific lymphoid cells enriched for histocompatibility (H-2) antigens. (1979) (0)
Selective Regulation of Cytokine Induction by Adenoviral Gene Transfer of IκBα into Human Macrophages: Lipopolysaccharide-Induced, But Not Zymosan-Induced, Proinflammatory Cytokines Are Inhibited, But IL-10 Is Nuclear Factor-κB Independent (1999) (0)
Using kannabidiol as anti-inflammatory agents (1999) (0)
Ia and macrophages in alloproliferation and allocytotoxicity. (1982) (0)
WILLIAMS, RICHARD O (Richard) (2005) (0)
Mono clonal antibodies against antigen specific factors (1981) (0)
Xth European Workshop for Rheumatology Research (2005) (0)
Antigen-T Lymphocyte Interactions in the Induction of Functional Unresponsiveness (1985) (0)
Exploring mechanisms of inflammatory hyperalgesia in murine collagen-induced arthritis (2005) (0)
Monoclonal Antibodies to Antigen Specific Factors — A New Tool for their Analysis (1983) (0)
Advanced glycation end products (AGE) enhance vascular endothelial growth factor (VEGF) production in promonocytic leukaemia THP-1 cells (2003) (0)
Inhibition of tissue factor induction by blockade of the nuclear factor-kappa B pathway in human macrophages and endothelial cells using adenoviral gene transfer: Nuclear factor-kappa B as a potential therapeutic target for plaque stabilization (2001) (0)
Enhancement of fracture repair by upregulation of the innate immune response (2014) (0)
An inflammatory cytokine signature predicts COVID-19 severity and survival (2020) (0)
Anti-TNF / TNF receptor and methotrexate in the treatment of autoimmune diseases. (1997) (0)
In memoriam: Professor Brian Maurice John Foxwell, 1956 to 2008 (2009) (0)
IL-10enhances expression oftheIL-2receptor achainonT cells (1994) (0)
Mo-P2:211 Inhibition of tissue factor signalling reduces production of pro-inflammatory cytokines in atheroma smooth muscle cells (2006) (0)
Retroviral Gene Therapy Nonobese Diabetic Mice by an IL-4-Based Mediating Active Tolerance Is Potentiated in The Activity of Immunoregulatory T Cells (2001) (0)
Recombinant lymphokines and their receptors (1989) (0)
Lymphokine Production in Autoimmunity: Usefulness of mRNA Assays (1987) (0)
Mal / TIRAP selectiveproduction in human myeloid and non-myeloid cells defined by B activation and cytokine κ Distinct pathways of LPS-induced (2003) (0)
Mixed lymphocyte culture and cell mediated cyto toxicity reactivity and specificity of idiotype specific lymphoid cells enriched for histo compatibility h 2 antigens (1979) (0)
Response of T Cells to Synthetic Peptide Antigens: Specific Unresponsiveness Analogous to Tolerance (1985) (0)
Erratum: c-erbB-2 Oncoprotein in screen-detected breast carcinoma: An immunohistological study (International Journal of Cancer (1993) 55 (63-65)) (1994) (0)
Helper Factors (1978) (0)
Immunotherapy of Autoimmune Diseases (1998) (0)
INTEGRATION OF SIGNALS IN THE IMMUNE RESPONSE (1980) (0)
YIA 1 Toll-like receptor 3 expression is increased in atherosclerosis and confers protection against early atherosclerotic lesion development and weight gain in apolipoprotein E deficient mice (2011) (0)
A view from a European medical academic who spends time in the US. (2009) (0)
Early Biochemical Events in T Lymphocytes Activated by Anti T3 (1985) (0)
Originals Interleukin-6 loealisation in the synovial membrane in rheumatoid arthritis (0)
Anti TNF therapy in rheumatoid arthritis (2007) (0)
Irf5- related treatment and screening (2012) (0)
I (cid:1) B kinase 2 but not NF- (cid:1) B–inducing kinase is essential for effective DC antigen presentation in the allogeneic mixed lymphocyte reaction (2003) (0)
10. Human helper factors induced in vitro (1978) (0)

This paper list is powered by the following services:

Other Resources About Marc Feldmann

en.wikipedia.org

What Schools Are Affiliated With Marc Feldmann?

Marc Feldmann is affiliated with the following schools:

Marc Feldmann's Academic­Influence.com Rankings